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 Obesity and diabetes are major public health concerns worldwide that contribute 
to cardiovascular disease, hypertension, and stroke. Research over the last two decades 
has revealed an important role for adipose tissue (AT) in the regulation and control of 
whole-body metabolic homeostasis and that chronic AT inflammation is an important 
pathogenic mechanism that links obesity and diabetes. While it is now recognized that 
inflammation is increased in AT with obesity, studies are underway to identify key 
inflammatory mediators and their downstream pathways that contribute to adipocyte 
inflammation. Therefore, data presented in this dissertation demonstrate that three novel 
mechanisms that may mediate obesity-induced inflammation in adipocytes.   
 Interleukin (IL)-12 family cytokines are heterodimeric proteins mostly expressed 
in classic immune cells and play critical roles in innate and adaptive immunity. However, 
recent evidence has shown that plasma levels of IL-12 family cytokines are elevated in 
obesity and diabetes, yet little has addressed a role for IL-12 family cytokines in 
adipocytes under any condition. Data presented in this dissertation demonstrate that 
various IL-12 family members are highly induced in AT under conditions of genetic and 
diet-induced obesity that is associated with increased inflammation and IR. 
Subsequently, we show that both preadipocytes (PAs) and adipocytes (ADs) secrete IL-
27 in response to inflammatory stress and demonstrate a novel function of IL-27 in 
adipocytes that is dependent on environmental cues.  
 While PAs and ADs both secrete IL-27 protein, divergent mRNA regulation of the 
IL-27 subunits (i.e., p28 and EBI3) was observed in response to tumor necrosis factor α 
(TNFα) in adipocytes. As our data indicated a role for epigenetic modifications in 
differential IL-27 mRNA expression, we further determined that histone deacetylases 
(HDACs) play a key role in TNFα-induced p28 gene expression. Thus, these data 
demonstrate that epigenetic modification of histones potentially regulates the divergent 
outcomes observed with p28 and EBI3 gene expression during inflammatory stress.  
 While extensive studies have identified TNFα as a master cytokine involved in AT 
inflammation, questions regarding its inflammatory actions on gene expression remain 
unclear. Emerging evidence highlights an important role for the Golgi apparatus (GA) in 
TNFα-induced inflammation, in part, through TNF receptor (TNFR) storage and secretion 
to the cell-surface, thus allowing for TNFα signaling. Our findings demonstrate a critical 
role for the GA in TNFR cell-surface expression and TNFα signaling as well as suggest a 
novel mechanism for the GA in TNFα-induced inflammation that potentially involves 
Golgi-localized co-factor(s) necessary for transcriptional gene expression. Collectively, 
data presented in this dissertation provide seminal evidence for novel mechanisms 
regulating adipocyte inflammation, potentially linking obesity with metabolic diseases.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Significance of Research 
 Obesity and diabetes mellitus are major public health concerns that globally 
afflict millions of individuals and subsequently lead to cardiovascular disease, 
hypertension, stroke, and neuropathies. The prevalence of obesity and diabetes has 
increased worldwide to 1.6 billion and is projected to double by 2030, highlighting an 
urgent need to delineate the molecular mechanisms that link these diseases and, 
therefore, allow for the development of better therapeutical strategies. Experimental and 
clinical evidence has established that chronic, low-grade inflammation links obesity to 
insulin resistance (IR) and ultimately diabetes. This is readily evident in preclinical 
animal models of obesity where genetic and pharmacological attenuation of pro-
inflammatory cytokines and chemokines improved insulin signaling. Moreover, these 
studies highlight adipose tissue (AT) as a critical regulator involved in the secretion of 
adipocyte-derived cytokines and chemokines (i.e., adipokines), implicating AT in the 
direct regulation of obesity-induced IR. However, key mechanisms mediating obesity-
induced inflammation in AT remain unresolved. Tumor necrosis factor (TNF) α is a 
pluripotent cytokine that mediates multiple inflammatory processes and immune 
responses. It has been clearly demonstrated that increased TNFα induces inflammatory 
gene expression and IR in AT during development of obesity. However, underlying 
mechanisms involving regulation of TNFα-induced inflammatory cascades in adipocytes 
are still unclear. As AT inflammation plays a central role in obesity-induced IR and 
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diabetes, the proposed research is significant as it establishes three novel mechanisms 
regulating adipocyte inflammatory gene expression. The objectives of this dissertation 
are to 1) characterize obesity-induced regulation of Interleukin (IL)-12 family cytokines in 
insulin-responsive tissues and cultured adipocytes, 2) elucidate novel mechanisms 
regulating IL-27 by histone deacetylases under conditions of inflammatory stress, and 3) 
investigate a novel role of the Golgi apparatus in mediating TNFα-induced inflammatory 
gene expression in adipocytes. The literature relevant to this research project is 
reviewed below. 
 
Review of Literature 
Obesity and diabetes. The prevalence of obesity has risen sharply in the United 
States in recent years. Among adults aged 20 years or older, 33.9 % are clinically 
obese, (1) as defined by a body mass index (BMI) of 30 kg/m2 or above. The sharp rise 
in obesity has been linked to increased type 2 diabetes (T2D) and cardiovascular 
disease, leading to public health concerns and plaguing an already overburdened health 
care system with costs approaching $140 billion annually (2,3). While the onset and 
progression of obesity is influenced by genetic, social, cultural, and environmental 
factors, it is generally recognized that excessive energy consumption and a sedentary 
lifestyle directly contribute to excess AT mass (4). Furthermore, it is widely accepted that 
increased fat accumulation in humans and animals correlates directly with the 
development of insulin resistance (IR) and ensuring diabetes. Indeed, weight loss 
therapy in obese adults was shown to concurrently improve pancreatic β-cell function, 
decrease plasma glucagon concentrations, and improve insulin action (5). In addition, 
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weight loss through exercise has been shown to enhanced fat oxidation and improved 
insulin sensitivity in obese adults (6). 
The World Health Organization (WHO) estimates that more than 1.1 million 
people die each year because of diabetes (7).  More alarming, death due to diabetes is 
expected to grow, as prevalence rates have risen to 171 million and are projected to 
double by 2030 (8). Concomitant with these statistics, prevalence estimates from the 
National Health and Nutrition Examination Survey (NHANES) concluded that 
approximately 26 million U.S. adults are diabetic (i.e., fasting blood glucose (FBG) > 126 
mg/dL) and another estimated 79 million pre-diabetic (i.e., FBG of 100-125 mg/dL). 
Similar to obesity, increased prevalence of diabetes contributes to increased 
cardiovascular disease, stroke, kidney failure, and amputation. These diabetes-linked 
co-morbidities add burden to the health care system with costs reaching $376 billion per 
year (9). As diabetes is coupled to the epidemic rise in obesity, it is not surprising that 
the number of adults and children diagnosed with diabetes continues to rise. Based on 
these statistics, increased knowledge concerning mechanisms regarding obesity-
induced IR will become vital for disease prevention and treatment of future generations.  
Adipose tissue as an endocrine organ. Obesity is characterized by expansion 
of AT mass. AT is a complex, highly innervated organ primarily composed of adipocytes 
and determined, but undifferentiated preadipocytes as well as fibroblasts, nerve cells, 
endothelial cells, smooth muscle cells, macrophages, and lymphocytes. Together, these 
diverse cell types in AT function as an integrated unit that dynamically regulates energy 
homeostasis. Historically, AT was regarded simply as a storage depot for excess energy 
during periods of caloric abundance. Research from recent years has determined that 
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AT has a much more complex and dynamic function as it acts as an endocrine organ 
secreting various factors into the blood. In 1987, the endocrine role of AT was first 
introduced, where it was observed that adipsin was secreted from adipocytes (10,11). 
The subsequent identification and characterization of leptin, an adipose-derived 
hormone regulating whole-body energy homeostasis, firmly established AT as an 
endocrine organ (12,13). It is now clear that AT secretes a plethora of peptide 
hormones, cytokines, or non-peptide biologically active molecules, which play a critical 
role in vascular homeostasis, immunity, and energy metabolism in tissues such as liver, 
muscle, and heart. While several key factors have been suggested to alter AT function 
and trigger IR, the onset of inflammatory gene expression has clearly been identified as 
a critical event coupling obesity to IR.  
Obesity, inflammation, and insulin resistance. It is now well-established that 
chronic, low-grade inflammation within AT plays a key role in linking obesity to IR and 
subsequently T2D (14). Several investigators have shown that chemokine and cytokine 
levels are increased during obesity, while ablation of these pro-inflammatory molecules 
improves insulin signaling. What triggers AT inflammation remains a heated topic of 
debate; however, recent studies suggest that endoplasmic reticulum (ER) stress is 
crucial for the initiation and integration of inflammatory pathways. The ER plays a critical 
role in protein folding, maturation, storage, transport, and lipid metabolism (15). It has 
been suggested that obesity over-exerts ER actions and, therefore, uncouples metabolic 
homeostasis within the adipocyte leading to IR. Accordingly, it has been shown that 
nutrient excess (e.g., glucose and free fatty acids) leads to ER dysregulation, thus 
initiating and subsequently activating inflammatory signaling cascades mitogen-activated 
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protein kinases (MAPKs), particularly c-Jun N terminal kinase (JNK), and nuclear factor 
kappaB (NF-κB) that promote inflammation (16-18).  
 Oxidative stress is a second mechanism implicated in the initiation of 
inflammation during obesity. Nutrient overload in AT has been shown to disrupt 
mitochondrial function leading to over-production of reactive oxygen species (ROS). 
Elevated levels of ROS impose oxidative damage and activate inflammatory signaling 
cascades within adipocytes. In addition to mitochondrial dysfunction, increased fat 
accumulation and BMI are closely correlated with increased systemic oxidative stress 
(19-21). Thus, it is not surprising that studies link increased ROS production during 
obesity to the activation of MAPKs and NF-κB and subsequently IR. Moreover, 
hyperglycemic conditions derived, in part, from decreased insulin sensitivity further 
exacerbate ROS production in adipocytes enhancing pro-inflammatory conditions (22).  
  Taken together, ER and oxidative stress, alone or in combination, promote 
chronic inflammation through the activation of inflammatory signaling pathways, in 
particular JNK and NF-κB. It is well established that both signaling pathways increase 
the production of pro-inflammatory cytokines in adipocytes, including tumor necrosis 
factor α (TNFα), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) 
(23). Activation of inflammatory signaling pathways within the adipocyte leads to 
enhanced AT inflammation through paracrine and endocrine actions of secretory 
proteins such as MCP-1 (24-26). MCP-1 functions predominantly as a chemoattractant 
protein highly specific for monocyte and macrophage recruitment to AT during obesity 
(Fig.1.1). Ligand binding of MCP-1 to the MCP-1 receptor (i.e., CCR2) on macrophages 
promotes macrophage chemotaxis to AT as well as the subsequent activation and 
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secretion of pro-inflammatory cytokines including TNFα into the local milieu (27,28). 
Therefore, adipocyte dysfunction and macrophage accumulation play an important role 
in regulating AT inflammation that contributes to obesity-induced IR (Fig.1.1). 
However, the plethora of inflammatory factors, that increase during obesity and 
regulate AT inflammation and IR, remain unresolved. It has been suggested that 
immunity and metabolism co-developed as functional relationships closely shared by 
adipocytes and macrophages (29-31). For example, both adipocytes and macrophages 
can be activated by pathogens (e.g., lipopolysaccharide) and secrete cytokines with pro- 
and anti-inflammatory properties (32). Moreover, the initiation and maintenance of 
immunity is metabolically demanding and cannot operate efficiently during conditions of 
energy deficit (33). Thus, the evolutionary pressures to survive would have favored 
energy efficiency and storage for times of food deprivation. Antithetically, co-evolutionary 
development is thought to drive chronic, low-grade inflammation during modern periods 
of human existence where nutrient excess is high. This is clearly evident in AT of obese 
individuals, where levels of pro-inflammatory cytokine, TNFα, are elevated under 
conditions of energy overload (33,34). As genetic or pharmacological ablation of this 
cytokine blunts chronic low-grade inflammation, it has been suggested that TNFα play a 
critical role in the development of obesity-induced IR and progression to T2D. 
 Adipocyte and immuno-modulatory cell interactions. Recent evidence 
demonstrates a prominent role for different immune cells in the regulation of AT 
inflammation and the development of IR in the pathophysiology of obesity. In addition to 
macrophages and monocytes, natural killer (NK) cells can infiltrate AT (35-37). 
Moreover, recent data demonstrate that various lymphocytes, including T regulatory 
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(Treg), T helper (Th), and T effector (Teff) cells, as well as B cells localize in AT 
depending on the stage of obesity (36,38,39). Indeed, studies suggest that T 
lymphocytes are present in AT even before macrophage infiltration, and that this early 
infiltration activates inflammatory signaling pathways that drive production of pro-
inflammatory chemokines like MCP-1, thus stimulating macrophage accumulation (36). 
These observations suggest that cross-talk between different immuno-modulatory cell 
types play a critical role in the development of AT inflammation and IR (40,41). 
Collectively, these studies demonstrate that cytokines and chemotactic mediators from 
multiple cell types work in concert with infiltrating immune cells to drive and exacerbate 
the inflammatory process in AT.   
IL-12 family cytokines. While it is now well recognized that an array of 
inflammatory cytokines and chemokines (e.g., TNFα, IL-6, and MCP-1) are increased in 
AT with obesity, extensive studies are underway to identify other inflammatory mediators 
that contribute to inflammation and chronic metabolic diseases like T2D. IL-12 family 
cytokines are heterodimeric proteins that are predominantly expressed in antigen-
presenting cells and play central a role in innate and adaptive immunity (42). IL-12 family 
cytokines respond to pathogens and activate cell-mediated antigen-specific defense 
mechanisms, which include increased expression of cytokines (43). IL-12 family 
cytokines include IL-12, IL-23, IL-27, and the recently identified IL-35. Each cytokine is 
composed of an α chain (i.e., p35, p19, and p28) and a β chain (i.e., p40 and Epstein-
Barr virus-induced gene (EBI) 3) that dimerize and signal through unique heterodimeric 
receptors composed of IL-12Rβ1, IL-12Rβ2, IL-23R, gp130, and WSX-1 (44) (Fig.2.1). 
IL-12 family cytokines share structural homology to IL-6. The α chain is homologous to 
other single-chain cytokines, such as IL-6, whereas the β chain shares homology to the 
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soluble form of IL-6Rα chain, suggesting that IL-12 family cytokines evolved from a 
member of the IL-6 cytokine superfamily. In keeping, IL-12 family cytokines are now 
considered part of the IL-6 superfamily (45,46). While pairing between IL-12 cytokine 
subunits and receptors is conserved, the origin, activity, and kinetic expression are cell-
type and condition specific. Similar to other pro-inflammatory cytokines, the production of 
IL-12 family cytokines is controlled by positive and negative regulatory elements. 
However, expression of both gene subunits (i.e., αand βchains) within the same cell is 
thought to be necessary for secretion of a biologically active cytokine (47,48).  
 The first member of the IL-12 cytokine family that was identified was IL-12. IL-12 
is composed of two disulfide-linked subunits p35 and p40 and is predominantly secreted 
from phagocytes, including macrophages, monocytes, neutrophils, and dendritic cells 
(DCs). These cell types play a critical role in immuno-regulatory actions, particularly 
through interferon (IFN) γ production and Th1 responses (46). In vitro and in vivo studies 
have shown that p40 can be secreted as a free monomer or homodimer (49,50), and 
that this IL-12p40 monomer/homodimer is not biologically active, but instead acts as an 
antagonist to the IL-12 heterodimer. Intriguingly, monomer/homodimer antagonism has 
only been demonstrated in mice and does not occur in humans (49). IL-12 signaling 
occurs when the IL-12 heterodimer binds IL-12Rβ1 and IL-12Rβ2. Receptor binding 
triggers transphosphorylation and subsequent activation of the Janus Kinase 
(JAK)/Signal Transducer and Activator of Transcription (STAT) pathway that ultimately 
results in phosphorylation of cytosolic and nuclear events involved in inflammation.  
While IL-12 is composed of the p35 (α chain) and p40 (β chain) subunit, the p40 
chain can also dimerize with p19 to form IL-23 (51). The discovery of IL-23 
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demonstrated a chain sharing characteristic that has since been described for the other 
IL-12 family cytokines. IL-23 binds IL-12Rβ1 and IL-23R, thus stimulating the JAK/STAT 
signaling pathway (43,51). IL-23 signaling through the JAK/STAT pathway drives IL-17 
expression that in turn promotes the Th 17 cellular response. The third member 
identified in the IL-12 family is IL-27, which is composed of p28 (α chain) and EBI3 ( 
chain) (52). Finally, the most recently identified member of IL-12 family is IL-35. IL-35 is 
composed of p35 and EBI3 (53). IL-35 is mainly produced in Treg cells and exerts 
suppressive effects on T cell proliferation. Receptors for IL-35 remain unclear; although 
it has been hypothesized that IL-12Rβ2 and WSX-1 or gp130 serve as receptors for IL-
35. While these cytokines share structural properties, divergent functions have been 
described for IL-12 family cytokines in the promotion of the immune response (44,54). 
IL-27. As mentioned above, IL-27 is composed of p28 and EBI3. While most 
studies demonstrate that IL-27 secretion is restricted to myeloid cells including 
monocytes, monocyte-derived DCs, and macrophages (55), recent studies indicate that 
IL-27 is also regulated in non-immune cells. For example, EBI3 and p28 were expressed 
in syncytio-trophoblasts and extravillous trophoblasts throughout human pregnancy (56). 
Moreover, p28 and EBI3 were highly expressed in regions of vascular smooth muscle 
cells and endothelial cells in response to pro-inflammatory stimuli (e.g., TNFα and IFNγ). 
These studies further demonstrate that regulation of IL-27 is NF-κB dependent, as IL-27 
expression was attenuated in the presence of the peroxisome-proliferator activated 
receptor (PPAR)γ agonist, rosiglitazone that blocked NF-κB binding to regulatory 
elements within the EBI3 gene (57). Subsequent studies support a key role for NF-κB in 
the regulation IL-27. This is apparent in conventional DCs exposed to docosahexaenoic 
acid (DHA), where lipopolysaccharide (LPS)-induced expression of IL-12 family 
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cytokines including IL-27 was suppressed through NF-κB inhibition (58). Additionally, 
studies using NF-κB-deficient mice clearly demonstrate a role for NF-κB as the 
predominant regulator of inducible p28 and EBI3 gene expression in classical immune 
cells (55,59). However, the transcriptional regulation of IL-27 in non-immune cells 
remains largely unknown.   
IL-27 is a unique IL-12 family member as reports have discerned two distinct 
functions in its regulation of the immune response: one as an initiator and the other as 
an attenuator of immune/inflammatory responses. IL-27 is a key cytokine that drives 
naïve T cells into the Th 1 subset at the initial step of differentiation. Upon differentiation, 
IL-27 actions reverse and subsequently inhibit activated Th cells. It is unclear why and 
how IL-27 exerts pro- and anti-inflammatory actions, however, recent studies 
demonstrate that differential IL-27-mediated regulation of STAT signaling pathways is 
essential for these contradictory actions (60). IL-27 binds to its heterodimeric receptor 
composed of gp130 and WSX-1, also known as T cell cytokine receptor (TCCR) (53). IL-
6 family cytokines (i.e., gp130 cytokines) including IL-11, oncostatin M, leukemia 
inhibitory factor, cardiotrophin 1, and neuropoietin also use gp130 as a receptor 
component required for both ligand binding and signal transduction (61,62). Hence, IL-
27 is also considered a gp130 cytokine that may share similar functions to that of IL-6. 
 IL-12 family, obesity, and inflammation. Recent evidence highlights the IL-12 
family cytokines as prospective regulators linking obesity to IR. While plasma levels of 
select IL-12 family members are elevated with obesity, diabetes, and metabolic 
syndrome (63-66), their cellular origin has not been fully determined. Still, IL-12 family 
expression in response to nutrient overload and inflammatory signals in macrophages, a 
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major player in the development of AT inflammation, has been investigated. High levels 
of glucose (HG) have been shown to increase IL-12 gene and protein expression in 
mouse peritoneal macrophages (66). In addition, IL-12 mRNA expression is highly 
elevated in type 1 diabetic (T1D) mice and T2D mice compared to control littermates 
(64). These findings suggest that hyperglycemia promotes IL-12 gene and protein 
expression. Moreover, HG induces inflammatory signaling pathways including p38, JNK, 
and NF-κB in macrophages, where inhibition of these signaling pathways suppressed 
HG-induced IL-12 mRNA expression (66,67). Recent studies demonstrated that obese 
mice exhibited significantly increased mRNA levels of p40 in parallel with IL-6 and TNFα 
expression in epididymal AT (68,69).  Although these studies suggest that AT can be an 
important source of IL-12 family cytokines under different conditions, their cellular origin 
has not been fully elucidated. Additionally, as evidence has established a mechanistic 
role for the gp130 cytokine in obesity-induced inflammation and IR (70-72), it has been 
hypothesized that IL-27, a recognized gp130 cytokine, potentially mediates obesity-
induced IR, inflammation and T2D. These findings support a possible role for IL-12, IL-
27, and other family members, as important mediators in obesity-induced AT 
inflammation linking excess nutrient intake to IR and diabetes. Finally, the functional 
relationships closely shared with adipocytes and macrophages, suggests that adipocytes 
produce IL-12 family cytokines in response to inflammatory stress, leading to the 
pathogenesis of obesity-induced inflammation and IR. 
TNFα. As an active endocrine organ, AT secretes proinflammatory cytokines, 
chemokines, growth factors, and complement proteins called “adipokines,” that regulate 
systemic tissue metabolism, lipid metabolism and insulin sensitivity (73,74). As a result 
of the excess production of these pro-inflammatory adipokines, AT enters a state of 
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chronic inflammation that includes macrophage infiltration (75-78). The most noted and 
well-studied adipokine involved in obesity-induced inflammation and IR is TNFα. TNFα 
was originally identified as a mediator that caused necrosis of tumors in mice infected 
with endotoxin (79). Subsequent studies later reported that TNFα enhanced muscle 
wasting (cachexia) (80) as well as dyslipidemias (81). Today, TNFα is a well-defined 
cytokine that regulates multiple biological activities such as cell fate, immune function, 
cytokine production, and IR (82). TNFα is produced by a variety of cell types, including 
macrophages, lymphocytes, fibroblasts, and adipocytes in response to inflammation, 
infection, injury, and other environmental stresses (83).  
 TNFα is synthesized as a 26-kDa plasma membrane-associated monomer 
(mTNFα) that undergoes proteolytic cleavage by metalloprotease, TNFα converting 
enzyme (TACE) to produce a 17-kDa soluble TNFα (sTNFα) molecule (80,84). Both the 
membrane bound and soluble forms of TNFα have been shown to mediate cellular TNFα 
action through the binding of two distinct receptors, TNFα receptor (TNFR)-1 and 
TNFR2. Similar to sTNFα, the transmembrane form of both receptors can be released 
into circulation via proteolytic cleavage by TACE. Release of soluble TNFR into 
circulation is currently used as a marker for increased inflammation and disease 
pathology. TNFR1 and TNFR2 share homology in the extracellular TNF binding domains 
and have similar binding affinity for TNFα, yet studies support separate cytoplasmic 
actions for these receptors that consequently result in different biological outcomes (85-
87). For instance, studies have shown that signaling from TNFR1 predominantly 
regulates inflammatory gene expression and IR in AT (87,88), while the consequences 
of TNFα-mediated TNFR2 signaling in AT remains unresolved. However, TNFR2 has 
been shown to increase the sensitivity of cells to TNFα as well as assist TNFR1 with 
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ligand binding through a process known as ‘ligand passing’, in which TNFR2 binds TNFα 
and passes bound TNFα to an open TNFR1 (89). However, the importance of ‘ligand 
passing’ in AT inflammation is not yet known.   
TNFα and adipocyte. A role for TNFα in obesity-induced IR was first 
documented in the early 1990s. It was observed that obese diabetic rodents expressed 
elevated levels of TNFα compared to wild-type littermates, while neutralization of TNFα 
in obese animals improved insulin sensitivity (90). Since this initial report, elevated levels 
of TNFα have subsequently been shown in human obesity and directly correlated to 
increased adiposity and IR (91). TNFα can function in both an autocrine or paracrine 
manner within AT to promote inflammation. Moreover, some studies, while controversial, 
suggest an endocrine role for TNFα on systemic IR (92). Regardless of its endocrine 
role, evidence over the last 20 years clearly demonstrates that TNFα signaling plays a 
pivotal role in coupling obesity to IR in adipocytes (93,94). In addition, several 
downstream mechanisms have been clearly defined for TNFα signaling in the 
development of IR in adipocytes.  
One mechanism by which TNFα impairs insulin sensitivity in adipocytes is 
through the regulation of cytosolic proteins that blunt insulin signaling and glucose 
uptake. Under normal physiologic conditions, insulin can bind to and activate its tyrosine 
kinase insulin receptor. Once activated, the insulin receptor phosphorylates select 
tyrosine residues on downstream targets including insulin receptor substrate (IRS) 
proteins (i.e., IRS-1, -2, -3, and -4) (95). Tyrosine phosphorylated IRS-1 activates the 
phosphatidylinositol 3-kinase (PI3K/AKT) pathway that stimulates glucose transporter 4 
(GLUT4) translocation to the plasma membrane and, thus, increases glucose uptake 
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(92,96,97). TNFα interferes with these signaling events downstream of the insulin 
receptor leading to decreased insulin sensitivity. Most notably, TNFα-activated JNK and 
IKK phosphorylate IRS-1 serine residue (S307), which blunts activation of PI3K (98) and 
inhibits tyrosine phosphorylation leading to the dissociation of IRS proteins from the 
insulin receptor (99,100). Collectively, these events impair GLUT4 translocation and 
cellular glucose uptake.  
  While TNFα can inhibit insulin signaling through cytosolic actions, early reports 
demonstrated a regulatory role for TNFα on nuclear gene expression (14). For example, 
TNFα suppresses gene expression of many proteins required for insulin-regulated 
glucose uptake, such as IRS-1 and GLUT4 (101-103). Furthermore, TNFα down-
regulates genes critical for adipocyte function and metabolism, such as 
CCAAT/enhancer binding protein α (C/EBPα) and PPARγ (92). Finally, TNFα represses 
genes that encode components of the electron transport chain. Collectively, the nuclear 
repression of these TNFα targets contribute to dedifferentiation of the adipocyte, 
increased circulating fatty acids, and mitochondrial dysfunction (104), subsequently 
leading to impaired insulin signaling and heightened AT inflammation. While TNFα can 
suppress critical genes involved in adipocyte function, it can also promote expression of 
genes involved in ER stress, oxidative stress, and inflammation further exacerbating 
conditions within the local milieu (102). A well-known example of TNFα-mediated gene 
expression in adipocytes involves the up-regulation and secretion of MCP-1 that 
contributes to macrophage infiltration, while ablation of MCP-1 attenuates AT 
inflammation and IR. Indeed, subsequent studies have since shown that 
pharmacological or genetic loss of these TNFα-induced genes improves inflammation 
and insulin signaling (105). Of note, TNFα can also induce TNFα as well as TNFR1 and 
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TNFR2 gene expression (106), demonstrating a feed forward mechanism of TNFα 
signaling that contributes to the state of chronic, low-grade inflammation.  
  TNFα signaling. Two major signaling pathways: MAPKs and NF-κB, sit at the 
nexus of TNFα action in both the nucleus and cytosol (26). Studies clearly highlight 
these two signaling pathways as instrumental in obesity-induced IR, as levels of MAPK 
and NF-κB activity are increased in vitro and in vivo and have been linked to impaired 
insulin sensitivity (100,107-109). More specifically, activation of these two signaling 
pathways is central to mediating actions of TNFα in the cytosol (i.e., serine 
phosphorylation of IRS-1) as well as the nucleus (i.e., adipocyte gene repression and 
inflammatory gene expression), thus promoting AT inflammation and IR (75,83,110).  
MAPKs. MAPKs consist of a family of highly conserved serine/threonine (S/T) 
protein kinases that include extracellular signaling-regulated protein kinase (ERK), JNK, 
and p38 (Fig.1.2). Phosphorylation of both threonine and tyrosine residues of the (T-X-Y) 
motif within the activation loop by upstream kinases is essential and sufficient for MAPK 
activation. Once activated, MAPKs can phosphorylate target proteins and transcription 
factors within the cytosolic and nuclear compartments (111-113). Transcriptional targets 
of MAPK activity include heterodimers of trans-acting factors (e.g., c-fos, c-Jun, ATF2) 
that are collectively referred to as AP-1 transcription factors. It is generally recognized 
that ERK is activated by growth factors and mitogens and is associated with cell survival 
and that JNK and p38 are stress activated (e.g., pro-inflammatory cytokines, UV 
irradiation, and reactive oxygen species) and associated with cellular stress and 
apoptosis (114). However, biological processes regulated by MAPKs are cell-type 
dependent. The MAPK signaling pathway has been shown to be activated in AT in 
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response to TNFα stimulation and serve as mediators of insulin signaling through 
cytosolic phosphorylation of specific serine residues of IRS-1 as well as induction of 
gene expression involved in impaired insulin actions (26,111,115-117).  
 NF-κB. TNFα also signals through the activation of the NF-κB pathway (Fig.1.2). 
The NF-κB transcription factor family consists of five members, p50, p52, p65 (RelA), 
p62 (RelB), and c-Rel that form homodimers and/or heterodimers to regulate gene 
expression (118). NF-κB activation is canonically regarded as the primary pathway 
downstream of inflammatory stimuli that regulate cytokine and chemokine gene 
expression. Each NF-κB family member plays a unique role that cannot be functionally 
substituted by other members of the family (119-121), suggesting that distinct NF-κB 
family members can differentially regulate transcriptional events during inflammation. 
Inactive NF-κB complexes are sequestered in the cytoplasm by a family of inhibitory 
proteins known as inhibitors of NF-κB (IκBs). NF-κB activation by inflammatory stimuli is 
initiated by phosphorylation of IκBα by the IκB kinase (IKK) complex resulting in 
degradation of IκBs. NF-κB is released from IκBα to translocate into the nucleus where it 
acts as a transcription factor involved in both repression and induction of gene 
expression (118,122). In addition to IκBα degradation, evidence demonstrates that 
posttranslational modifications of NF-κB subunits are necessary for the complete 
activation of NF-κB. One example of this includes the NF-κB subunit p65, where 
phosphorylation and acetylation alter transcriptional activity of NF-κB (123-125). Once 
activated, nuclear NF-κB dimers bind κB sites within the distal and proximal promoter of 
target genes and regulate transcription through the recruitment of co-activators and co-
repressors (126,127).  
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Co-regulators of NF-κB. Emerging evidence indicates that transcriptional 
activity of NF-κB is also regulated by transcriptional co-activators and co-repressors, 
which themselves can be targeted by multiple signal transduction pathways (126,127). 
Moreover, regulation of co-activators and co-repressors is cell-type and condition-
specific (128,129), potentially providing a mechanism for divergent biological outcomes 
assigned to transcription factors within the same family. For example, RIP140 is a well-
known transcriptional co-repressor of PPARs (130) that regulate glucose uptake and 
fatty acid oxidation in metabolically active tissues (131-134). Conversely, RIP140 can 
also act as a co-activator of inflammatory gene transcription in macrophages (135). 
Collectively, studies demonstrate that co-activator and co-repressor function is not 
universal and can act in an opposing manner depending on gene environments 
(136,137). 
The co-activators of NF-κB include CREB-binding protein (CBP/p300) and 
steroid receptor coactivator (SRC) proteins. CBP/p300 and the SRC proteins possess 
intrinsic histone acetyltransferase (HAT) activity. Histone acetylation serves an 
epigenetic function by acetylating specific lysine residues of nucleosomal histone 
proteins to alter the electrostatic properties of chromatin in manner allowing for gene 
transcription (138). The co-repressors of NF-κB include silencing-mediator for retinoid 
and thyroid hormone receptor (SMRT), nuclear receptor co-repressor (NCoR), and 
histone deacetylases (HDACs) (139-141). SMRT and NCoR do not possess enzymatic 
activity, but can trigger the catalytic activity of HDACs. In contrast to histone acetylation, 
HDACs function to deacetylate nucleosomal histones and alter chromatin in a manner 
that leads to gene repression (142).  
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HDACs. Epigenetic control encompasses heritable changes in gene expression 
or cellular phenotype caused by mechanisms other than changes in the DNA sequence. 
Aberrant transcription due to epigenetic modification on gene expression has been 
clearly linked to diseases including cancer and metabolic diseases (143). Emerging 
evidence has demonstrated that posttranslational modification of histone proteins by 
acetylation or deacetylation is important epigenetic phenomena that play critical roles in 
the modulation of chromatin topology and the regulation of gene expression (144). 
HDACs activity historically involves removal of acetyl groups from the nucleosomal 
histone proteins, influencing nucleosome structure and altering gene transcription (145). 
While histone acetylation is often correlated with gene activation, HDACs act to silence 
genes by reversing regulatory acetylation of histone proteins (Fig.1.3). Eighteen HDACs 
have been identified and divided into four classes based on similarity to yeast 
transcriptional regulators (146) (Table1.1). As their name indicates, it has generally been 
suggested that the activity of HDACs is directed at histone protein. Conversely, evidence 
using Drosophila and the yeast indicated that HDAC activity can contribute to gene 
activation (147-150). In addition, recent studies have shown that HDAC inhibition 
attenuates gene expression, suggesting HDAC activity is critical in activating some 
genes (151-153).  
It has been shown that many HDACs are at least partially cytoplasmic (154-157), 
and studies demonstrated their action on non-histone substrates, including transcription 
factors such as NF-κB (124). As it has been suggested that acetylation/deacetylation is 
also important regulation for signaling transduction and gene transcription, acting in a 
manner similar to phosphorylation and dephosphorylation (158), acetylation of NF-κB 
protein is required for transcriptional activation (123). p65, the subunit of NF-κB that 
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contains the transactivation domain, is acetylated by a general transcriptional coactivator, 
CBP, which possess intrinsic HAT activity, and the acetylation enhances the DNA 
binding activity of NF-κB (159,160) (Fig.1.4). Evidence apparently appears that HATs 
and HDACs target non-histone proteins throughout various cellular compartments, 
where estimates of approximately 3000 proteins are regulated by 
acetylation/deacetylation (161,162). Thus, it is not surprising that HDACs regulate NF-κB 
through deacetylation of regulatory elements within the NF-κB gene as well as 
modification of NF-κB protein (163,164). While central dogma suggests that HDACs lead 
to gene repression, others have shown opposing roles for HDACs on gene expression. 
Indeed, treatments with pan-HDAC inhibitors such as trichostatin A (TSA), which block 
all HDACs except class III, have been shown to both enhance and suppress gene 
expression (165). Not surprising then, HDAC inhibitors can promote NF-κB activity by 
increasing p65 acetylation (123,166,167) and diametrically act in an anti-inflammatory 
manner through the repression of inflammatory genes, demonstrating that HDAC activity 
is cell-type and environment specific (168-170).  
HDAC inhibitors. As HDACs appear to play an important role in the regulation of 
gene expression, deregulation of HDACs is associated with a variety of 
pathophysiological processes, including cancer, neurodegeneration, and inflammation 
(144). Since the first HDAC inhibitor, SAHA (Zolinza) was approved by the FDA for the 
treatment of cutaneous T-cell lymphoma (171), extensive studies have been underway 
to develop of novel small molecule inhibitors of HDACs. The general property of most 
HDAC inhibitors is a structure consisting of a zinc-binding group in the active site, 
deacetylase domain (150). There are four chemical classes of HDAC inhibitors: 
hydroxamic acids, short chain fatty acids, cyclic peptides, and bezamides (Table1.2). 
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While, relative potencies and selectivity of these HDAC inhibitors vary between and 
within classes (172), hydroxamic acid (i.e., TSA), which contains the greater zinc-
chelating properties, is recognized as a potent (i.e., nanomolar concentrations) pan-
HDAC inhibitor. In contrast, the short chain fatty acids are relatively less potent (i.e., 
milimolar concentrations) HDAC inhibitors as they provide modest selectivity towards 
class I HDACs. Cyclic peptides and benzamide HDAC inhibitors are generally highly 
selective for HDAC1, 2, and 3 (173). The class III HDACs, also known as sirtuins are 
NAD+ dependent HDACs also shown to play important roles in transcriptional regulation 
(174). Moreover, a few molecules have been discovered as inhibitor of sirtuins, including 
the vitamin, nicotinamide (175). While HDACs appear to be highly involved in the 
regulation of inflammatory gene expression, it is still unclear what role HDACs play in the 
transcriptional activation of inflammatory gene expression in adipocytes.  
TNFα and Golgi Apparatus. Although TNFα can bind and signal through 
TNFR2, most of its activity regarding inflammatory gene expression and IR occurs 
through TNFR1 where ligand binding leads to internalization of the ligand-receptor 
complex (176,177). While some TNFα mediated-events depend on internalization, 
others are terminated as the receptor is recycled through recycling endosomes back to 
the membrane with degradation of the ligand by lysosomal activity (178). If not recycled 
or replaced, the outcome of internalization would be a decrease in surface receptor 
density leading to a decrease in TNFα sensitivity. A similar loss in TNFR on the surface 
occurs following enzymatic cleavage of membrane bounded receptors by TACE 
resulting in truncated, non-functional, soluble receptors (i.e., sTNFR) that are known to 
play a role in dampening TNFα activity (179,180). Thus, vesicular trafficking of TNFR, 
either from the de novo synthesis in the ER or through recycling endosome is critical for 
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TNFα action. To this point, others have also reported that TNFR1 is predominantly 
localized to Golgi apparatus (GA) in a perinuclear compartment as opposed to cell 
surface expression providing a means to curtail receptor sensitivity when TNFα action is 
not warranted. As this pool of TNFR1 has been shown to translocate to the surface upon 
TNFα stimulation, it has also been suggested that the Golgi pool serves a reservoir to 
increase cell surface receptor density when TNFα action is warranted (181). It has also 
been demonstrated that the cytoplasmic domain of the TNFR1 possess a Golgi-
localization sequence (182,183), but how and under what conditions this localized 
trafficking occurs has yet to be determined. Furthermore, to date, Golgi-associated 
TNFR1 has been reported for only a few cell types suggesting the possibility of a cell-
type, condition-specific phenomenon (181,182,184). As studies have clearly 
demonstrated the dynamic nature of TNFR1 surface expression influenced by receptor 
internalization as well as receptor shedding, vesicular trafficking, which may or may not 
involve Golgi activity, represents an important regulatory mechanism mediating TNFα 
action. Despite the importance of TNFα signaling in the etiology of obesity-induced IR, 
no information regarding a role for the GA in regulating TNFα signaling in adipocytes has 
emerged. 
The Golgi Apparatus. The Golgi is a perinuclear organelle that modifies and 
packages proteins in route to their final destination within the cell. While many plasma 
membrane proteins (e.g., receptors) are modified in the Golgi, this organelle plays a 
critical role of packaging secretory proteins (e.g., ligands, cytokines) into vesicles prior to 
their transport to the cell surface for exocytosis. The Golgi organelle (commonly referred 
to as the ‘Golgi apparatus’) is comprised of stacks of membrane-bound structures known 
as ‘cisternae’ where each cisterna contains enzymes that modify and package proteins 
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that move through the organelle (Fig.1.5). The cisternae are arranged by structural and 
functional significance where newly synthesize proteins leaving the ER enter the Golgi at 
the cis-Golgi network (CGN), oriented in space nearest to the nucleus, and exit the 
trans-Golgi network (TGN) on the opposite face of the organelle in route to their final 
destination.  
Transport of protein cargo between different regions of the GA as well as 
between many organelles (e.g., ER) and structures (e.g., plasma membrane) involves 
‘budding’ of vesicles from the donor compartment (185,186). Formation of each vesicle 
is directed by a protein coat that forms a structural lattice that is critical for the budding 
process to occur. Each protein coat is specific for the region in which the vesicle is 
formed as well as its final destination, thereby playing a directing role in vesicular 
trafficking. COP-II proteins mediate vesicle budding of ER membranes and direct cargo 
export from the ER to the GA. Anterograde transport through the GA (i.e., away from the 
CGN) as well as retrograde transport (i.e., toward the CGN) is directed by COP-I protein 
coated vesicles. Transport from the TGN to final destination is directed by clathrin-
coated vesicles where clathrin is recruited by the adapter protein, AP-1, which is 
different from clathrin-coated vesicles originating from other donor membranes (e.g., 
plasma membrane) where the clathrin is recruited by different adaptor proteins. 
The coating of each vesicle with lattice proteins depends on small GTP-binding 
proteins such as Sar1 that initiates recruitment of COP-II proteins to ER vesicles and 
ADP-ribosylation factors (ARFs) that regulated COP-I recruitment to GA vesicles 
(187,188). ARFs cycle between active GTP-bound states and inactive GDP-bound 
states through GDP-GTP exchange mediated by guanine exchange factors (GEFs). The 
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ARF-GEFs, BIG1 and BIG2 are potently and reversibly inhibited by the fungal metabolite, 
brefeldin A (BFA) with a rare degree of specificity (189,190). At nanomolar 
concentrations, BFA induces the release and dispersal of all COP-I proteins from GA 
vesicles (Fig.1.5) as well as clathrin proteins that utilize specific adaptors (e.g., AP-1) 
leading to a collapse of the CGN to the ER and merging of the TGN with the microtubule 
organizing center. Following 20 years of investigation, there is strong consensus that the 
molecular targets of BFA are mostly confined to these GEFs where exposure to BFA at 
nanomolar concentrations results in rapid (< 2 mins) and reversible dispersal of GA coat 
proteins, thereby inhibiting GA functions (e.g., secretion) without affecting COP-II vesicle 
formation from the ER as well as clathrin-coated vesicles important for endosomal 
trafficking as well endocytosis or internalization receptors at the plasma membrane.   
Review Summary. Obesity and T2D are major public health concerns worldwide 
that contribute to cardiovascular disease, hypertension, and stroke. Research over the 
last two decades has revealed an important role for AT in the regulation and control of 
whole-body metabolic homeostasis and that chronic AT inflammation is an important 
pathogenic mechanism that links obesity and diabetes (2,25,191). Early evidence 
demonstrated a role for inflammation where it was discovered that TNFα was 
overproduced in AT of obese mice. TNFα is a major cytokine regulating AT function and 
metabolism by activating multiple signaling pathways in order to activate expression of a 
number of pro-inflammatory genes. Accumulation of macrophages and other immuno-
modulatory cells within AT along with adipokine secretion drives AT inflammation 
ultimately resulting in delipidation and systemic IR (14,23,192). While it is now 
recognized that inflammatory cytokines and chemokines are increased in AT with 
obesity, extensive studies are underway to identify other inflammatory mediators or 
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signaling pathways that contribute to adipocyte inflammation and IR. IL-12 family 
cytokines have emerged as a new mediators involved in obesity-related inflammatory 
diseases. Plasma levels of several IL-12 family cytokines have been shown to be up-
regulated in obesity and diabetes (63-65), yet limited studies have delineated the 
regulation and role for these molecules in the adipocyte under conditions of inflammatory 
stress. While others evidence has demonstrated a role that HDACs in regulating 
inflammatory gene expression, there are few reports addressing their role regarding 
inflammatory gene expression in adipocytes. Albeit, extensive studies have identified 
TNFα as a master cytokine involved in AT inflammation, questions regarding its 
inflammatory actions on gene expression remain unclear. Therefore, we proposed the 
following study objectives to elucidate novel mechanisms regulating inflammatory gene 
expression in adipocytes, potentially linking obesity to inflammatory diseases.  
 
Study Objectives 
 Chapter II. Inflammation is an important pathogenic mediator linking obesity and 
diabetes. Recent evidence highlights IL-12 family cytokines as prospective inflammatory 
mediators linking obesity to IR. However, little is known about regulation of this family 
cytokine with regards to obesity in insulin responsive tissues. Therefore, the objective of 
the study summarized in Chapter II is to examine the regulation of IL-12 family cytokines 
and receptors in insulin responsive tissues of genetic and diet-induced obese mouse 
models as well as cultured undifferentiated preadipocytes and mature adipocytes. We 
will 1) establish relative IL-12 family cytokine expression across tissue types and how 
obesity affects the expression, 2) determine regulation of IL-12 family cytokines in AT 
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during the development of obesity as these animals transition to an inflamed, insulin 
resistant state, and 3) elucidate the regulation and function of IL-12 family members in 
preadipocytes and adipocytes, as major, lineage-related cell types in AT.   
Chapter III. Although IL-27 plays an important role in initiating and maintaining 
cell-mediated immune responses, little is known regarding IL-27 in obesity-associated 
inflammation in adipocytes. As our previous study demonstrated a regulatory role for IL-
27 in obesity-induced inflammation, the objective of the study summarized in Chapter III 
is to: 1) establish divergent regulation of IL-27 genes, p28 and EBI3, in response to 
inflammation based on cellular phenotype, 2) determine upstream signaling pathways 
that regulate p28 and EBI3 expression in response to TNFα, and 3) elucidate that how 
HDACs are involved in epigenetic regulation of these two genes.  
Chapter IV. TNFα potently regulates inflammatory gene expression and IR 
through interacting with TNFR1 on the surface of the plasma membrane. As receptor 
internalization and receptor shedding lead to dynamic turnover of receptors on the 
surface, vesicular trafficking plays a critical role in mediating receptor density and TNFα 
action. As there is evidence that the GA may play a role in TNFR trafficking as well as 
serving as a reservoir for TNFR1 in other cell types, the objective of the study 
summarized in Chapter IV is to: 1) determine a regulatory role of the GA in TNFα-
induced inflammatory gene expression in adipocytes and 2) elucidate specific 
mechanisms involved in this regulatory process.  
  
26 
 
Table 1.1. Classification of Histone Deacetylases 
 
Class Enzyme Mechanism of deacetylase activity Subcellular localization 
I HDAC1 Zn2+ dependent Nuclear 
 
HDAC2 Zn2+ dependent Nuclear 
 
HDAC3 Zn2+ dependent Nucleocytoplasmic shuttling 
 
HDAC8 Zn2+ dependent Nuclear 
IIa HDAC4 Zn2+ dependent Nucleocytoplasmic shuttling 
 
HDAC5 Zn2+ dependent Nucleocytoplasmic shuttling 
 
HDAC7 Zn2+ dependent Nucleocytoplasmic shuttling 
 
HDAC9 Zn2+ dependent Nucleocytoplasmic shuttling 
IIb HDAC6 Zn2+ dependent Nucleocytoplasmic shuttling 
 
HDAC10 Zn2+ dependent Nucleocytoplasmic shuttling 
III SIRT1 NAD+ dependent Nuclear 
 
SIRT2 NAD+ dependent Cytosol 
 
SIRT3 NAD+ dependent Mitochondria 
 
SIRT4 NAD+ dependent Unknown 
 
SIRT5 NAD+ dependent Unknown 
 
SIRT6 NAD+ dependent Unknown 
 
SIRT7 NAD+ dependent Unknown 
IV HDAC11 Zn2+ dependent Nuclear 
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Table 1.2. Classification of Histone Deacetylase Inhibitors 
 
Group Compounds 
IC50 range in 
vitro 
Hydroxamic acids 
Trichostatin A (TSA) nM 
Suberoyl anilide bishydroxamide (SAHA) μM 
M-carboxycinnamic acid bishydroxamide 
(CBHA) 
μM 
Scriptaid μM 
Pyroxamide μM 
Oxamflatin nM 
Short-chain fatty 
acids 
Butyrate mM 
Phenylbutyrate mM 
Valproric acid mM 
Cyclic tetrapeptides 
 
Trapoxin nM 
HC-toxin nM 
Chlamydocin nM 
Depudesin μM 
Apicidine nM-uM 
Depsipeptide nM 
Benzamides 
N-acetyldinaline μM 
MS-275 μM 
Sirtuin (Class III) 
inhibitors 
Sirtinol 
 
Splitomicin 
 
Nicotinamide 
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Figure 1.1. Obesity-induced adipose tissue inflammation. Obesity is characterized by 
expansion of AT. As adipose tissue mass is continue to increase, adipocytes can secrete 
chemoattractant proteins (i.e., MCP-1) to recruit macrophages into AT. Infiltrated 
macrophages and enlarged adipocytes secrete a large amount of TNFα that stimulates PAs 
and ADs to activate inflammatory signaling pathways (i.e., MAPK and NF-κB) and gene 
expression, contributing adipocyte dysfunction and IR.  
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Figure 1.2. TNFα-induced inflammatory gene expression 
through MAPK and NF-κB signaling pathways.  
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Figure 1.3. Gene activation and repression are regulated by HATs and HDACs on 
core histones. HATs transfer acetyl groups (yellow star) to lysine residues on proteins, 
and HDACs catalyze removal of these groups. HATs acetylate on lysine residues in the 
N-terminal tail of histone proteins. Acetylated histone proteins change the chromatin 
structure from the resting closed conformation to an activated open form, allowing 
transcription factors binding to the promoter to initiate gene transcription. HDACs 
convert these actions, thereby causing gene silencing. CoA: coactivator; TF: 
transcription factor; Pol II: RNA polymerase II.  
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Figure 1.4. Acetylation of NF-κB for transcriptional activity. TNFα signaling 
activates IKK, which phosphorylates IκBα, leading to their degradation and the 
ensuring nuclear translocation of NF-κB and subsequent transactivation of NF-κB 
dependent genes. p65, the subunit of NF-κB that contains the transactivation domain, 
is acetylated by a general transcriptional coactivator, CBP, which possess intrinsic 
HAT activity. CBP also acetylates histone proteins to open up the chromatin. CBP: 
CREB-binding protein.  
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Figure 1.5. Vesicular trafficking in Golgi apparatus.  
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CHAPTER II 
 
OBESITY-INDUCED REGULATION OF IL-12 CYTOKINE FAMILY IN INSULIN-
RESPONSIVE TISSUES AND CULTURED ADIPOCYTES 
 
 
Abstract 
Obesity is a major public health concern worldwide that afflicts millions of individuals 
leading to diabetes, cardiovascular disease, hypertension, and stroke. Mounting 
evidence has established a role for chronic, low-grade inflammation in the development 
of obesity-induced insulin resistance (IR), as genetic ablation of pro-inflammatory 
cytokines and chemokines elevated in obesity improves insulin signaling in vitro and in 
vivo. Recent evidence highlights the interleukin (IL)-12 family cytokines as prospective 
inflammatory mediators linking obesity to IR. We examined, for the first time, the 
expression patterns of all IL-12 family members including receptors under conditions of 
obesity in the insulin responsive white adipose tissue (WAT), liver, skeletal muscle, and 
heart as obesity alters metabolism of these tissues leading to IR and diabetes. We 
demonstrate that IL-12 family cytokines and their cognate receptors were all expressed 
in the insulin responsive tissues examined, where eight of ten genes are most 
abundantly expressed in WAT. Moreover, we show that IL-12 family cytokines and 
receptors were divergently regulated under conditions of obesity in a tissue-specific 
manner. As most of the genes analyzed were predominantly expressed in WAT, we 
demonstrate that one family member, IL-27 was highly regulated in WAT based on the 
developmental stage of obesity as well as the inflammatory progression associated with 
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obesity. We further report that IL-27 is secreted from adipocytes in response to 
inflammatory stress and differentially regulates pro-inflammatory gene expression based 
on environment. Collectively, these findings suggest that divergent regulation of IL-12 
family cytokines, particularly IL-27 may contribute to tissue-specific inflammation during 
obesity.  
Introduction 
 Obesity and diabetes mellitus are major public health concerns worldwide 
leading to neuropathies, cardiovascular disease, hypertension, and stroke (1,2). 
Mounting evidence has established a role for chronic, low-grade inflammation in the 
development of obesity-induced IR (3-5). Several investigations have shown that 
chemokine and cytokine levels are increased during obesity, while ablation of any of 
these pro-inflammatory molecules improves insulin signaling in insulin responsive 
tissues (6,7). While WAT is recognized as a key site of cytokine expression in obesity, 
other insulin responsive tissues, such as liver, muscle, and heart also experience 
increased inflammation in the obese state (3,8-12). Therefore, obesity induces an 
insulin-resistant state in these tissues, resulting in an imbalance of systemic glucose 
homeostasis, consequently contributing to the pathological metabolic disorders 
associated with obesity. While it is now well recognized that an array of inflammatory 
cytokines and chemokines are increased in obese tissues, extensive studies are 
underway to identify inflammatory mediators that contribute to inflammation and 
ultimately chronic diseases like type 2 diabetes.  
Recent evidence highlights the IL-12 family cytokines as prospective regulators 
linking obesity to IR. While plasma levels of select IL-12 family members are elevated 
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with obesity, diabetes, and metabolic syndrome (13-16), their cellular origin has not been 
fully determined. IL-12 family cytokines are mostly expressed in antigen-presenting cells 
and play critical roles during inflammatory stress. The members of the IL-12 family are 
heterodimeric proteins consisting of an alpha chain and a beta chain (Fig.2.1). The alpha 
chains consist of p19, p28, or p35 that share structural homology with IL-6, whereas the 
beta chains, p40 or Epstein-Barr virus-induced gene 3 (EBI3), shares homology with 
soluble cytokine receptor chains, such as IL-6Rα (17,18). Dimerization of specific alpha 
chain and beta chain subunits form the IL-12 family that includes IL-12 (i.e., p35 and 
p40), IL-23 (i.e., p19 and p40), IL-27 (i.e., p28 and EBI3), and the newly identified IL-35 
(i.e., p35 and EBI3). Each cytokine signals through unique heterodimeric receptors 
composed of IL-12Rβ1, IL-12Rβ2, IL-23R, gp130, and WSX-1 (19). Evidence 
demonstrates that alpha and beta subunits must dimerize within the cell to produce and 
secrete biologically active cytokines known to play roles in linking innate resistance and 
adaptive immunity (20). Although the pairing between cytokine subunits and receptors is 
conserved, the origin, activity, and kinetic expression are cell-type and condition-specific.  
IL-27 is a unique IL-12 family member, as reports have discerned two distinct 
functions in its regulation of the immune response: one as an initiator and the other as 
an attenuator of inflammatory stress (21-23). IL-27, composed of p28 and EBI3, initiates 
its actions through cell-surface binding to its receptor composed of WSX-1 and gp130, 
where gp130 is required for both ligand binding and signal transduction. While historic 
literature demonstrate that IL-27 expression is restricted to myeloid cells including 
monocytes, monocyte-derived dendritic cells, and macrophages induced mainly by toll-
like receptor stimulation (21), more recent studies indicate regulation of IL-27 in other 
cell types. For example, p28 and EBI3 were highly expressed in regions of vascular 
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smooth muscle cells and endothelial cells with pro-inflammatory stimuli (i.e., TNFα and 
IFNγ) (24). Activation of the NF-κB signaling pathway by various inflammatory stimuli 
largely account for the transcriptional regulation of IL-27 (24,25). Plasma levels of 
several IL-12 family cytokines have been shown to be elevated in obesity and diabetes, 
yet their cellular origin has not been determined (13,14,26). As adipocytes displays 
macrophage-like features (27), expressing many of the same inflammatory genes, it 
could be hypothesized that several IL-12 family cytokines are expressed and secreted 
from adipocyte lineage and involved in obesity-associated inflammatory process. 
Additionally, evidence has established a mechanistic role for the gp130 cytokine in 
obesity-induced IR (28-30). These findings support a role for IL-27, in response to 
inflammatory stress, as an important mediator linking excess nutrient intake to IR and 
diabetes. 
In this investigation, we examined the regulation of the IL-12 family cytokines and 
their cognate receptors in response to obesity in WAT, liver, muscle, and heart, as these 
insulin responsive tissues centrally regulate glucose homeostasis and vascular function 
(11,31,32). As we report that IL-12 family expression is most abundant in WAT, this 
report further investigated the developmental role of obesity on IL-12 family regulation in 
WAT. With a potential role for IL-12 family cytokines in WAT, we used 3T3-L1 
adipocytes to show the regulatory role for IL-12 family, with focus on IL-27 in response to 
inflammation. This report supports a role for IL-12 family members, particularly IL-27, as 
important mediators linking obesity to inflammatory diseases.  
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Materials and Methods 
Materials. Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS), 
Trypsin-EDTA, and recombinant murine TNFα were purchased from Invitrogen. Fetal 
bovine serum (FBS) was obtained from HyClone. The following antibodies were used for 
immunoblot analysis: Phospho-STAT1 (Tyr701), phospho-STAT3 (Tyr705), phospho-
ERK (Thr202/Tyr204), phosphor-p38 (Thr180/Tyr182), phosphor-JNK (Thr183/Tyr185), 
and IκBα (Cell Signaling). Recombinant murine IL-27 was obtained from R&D Systems 
and lipopolysaccharide (LPS) was from Sigma. Enhanced chemiluminescence (ECL) 
reagents were obtained from Perkin-Elmer Life Sciences. All TaqMan primer probes 
used in this study were purchased from Applied Biosystems.  
Mice and experimental diets. Animals used for this study include genetically 
obese male B6.V-Lepob/J (B6-ob/ob) mice and their lean littermates as well as 
C57BL/6J mice rendered obese by diet and their lean controls. All mice were housed 
and treated by the supplier (Jackson Laboratories, Bar Harbor, Maine) until shipment 1 
wk prior to tissue harvest. B6-ob/ob mice and lean littermates were purchased for 
experimentation at 6 wks and 10 wks of age and given free access to a standard 
laboratory chow diet. C57BL/6J mice subjected to diet-induced obesity (DIO) were fed a 
high fat diet (HFD) consisting of 60% kcal from fat (Research Diets Inc. D12492) from 6 
wks of age. Lean C57BL/6J control mice were fed a control low fat diet (LFD) consisting 
of 10% kcal from fat (Research Diet Inc. D12450B) from 6 wks of age. Both diets 
contained 10% kcal from protein with the balance in caloric value provided by 
differences in carbohydrate content. Mice receiving both diets were given free access to 
food and shipped for experimentation at 18 wks and 24 wks of age. All animals were 
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euthanized by CO2 gas asphyxiation and epididymal AT, liver, calf skeletal muscle, and 
ventricular heart tissue collected and processed for preparation of total RNA. Animal 
care and use was in compliance with the Institute of Laboratory Animal Research Guide 
for the Care and Use of Laboratory Animals and approved by the Institutional Animal 
Use and Care Committee. 
Cell culture. The murine 3T3-L1 cell line was purchased from Howard Green, 
Harvard Medical School (33). Cells were propagated in DMEM supplemented with 10% 
CS until reaching density-induced arrest, as previously described (34). At 2 days post-
confluence, growth medium was replaced with DMEM supplemented with 10% FBS, 0.5 
mM 1-methy-3-isobutylxanthane, 1 µM dexamethasone, and 1.7 µM insulin (MDI) for 2 
days. Subsequently, cells were cultured in DMEM supplemented only with 10% FBS 
over the following six days as PAs differentiated into mature ADs. Throughout the study, 
‘time 0’ refers to density arrested cells immediately before the addition of MDI to the 
culture medium. Experiments described herein were conducted in density-arrested day 0 
(d0) PAs or day 8 (d8) ADs. All experiments were repeated 2-3 times to validate results 
and ensure reliability.  
Immunoblotting. Cell monolayer were washed with phosphate-buffer saline (PBS) 
and scraped into ice-cold lysis buffer containing 0.1 M Tris (pH 7.4), 150 mM NaCl, 10% 
sodium dodecyl sulfate (SDS), 1% Triton X, 0.5% Nonidet P-40 (NP40), 1 mM EDTA, 1 
mM EGTA. Phosphatase inhibitors (20 mM β-glycerophosphate, 10 mM sodium fluoride 
and 2 µM sodium orthovanadate) and protease inhibitors (0.3 µM aprotinin, 21 µM 
leupetin, 1 µM pepstatin, 50 µM phenanthroline, 0.5 µM phenylmethylsulfonyl fluoride) 
were added to lysis buffer immediately prior to cell harvest. Cell lysates were sonicated 
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and centrifuged (13,000g, 10 min, 4⁰C), and the supernatant transferred to a fresh tube. 
Protein content was determined by bicinchoninic acid (BCA) procedures according to 
manufacturer’s (Pierce, Rockford, IL) instructions. Equal amounts of whole cell lysate 
protein were separated by SDS-PAGE electrophoresis. Cell lysates were mixed with 
loading buffer containing 0.25M Tris (pH6.8), 4% SDS, 10% glycerol, 0.01% 
bromophenol blue, and 10% dithiothreitol, then heated at 80⁰C for 5 min prior to 
electrophoresis. Proteins were resolved on SDS-polyacylamide gel electrophoresis 
(PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore corp., 
Billerica, MA). After transfer, membranes were blocked with 4% milk and probed with 
indicated primary antibodies overnight at 4⁰C. Membranes were subsequently probed 
with horseradish peroxidase-conjugated secondary antibodies for 1hr at room 
temperature. Membranes were immersed in ECL and data visualized by 
autoradiography using CL-XPosure film (Pierce).  
Real-Time RT-PCR. For animal study, total RNA was isolated from epididymal 
AT, liver, skeletal muscle, and heart by utilizing Trizol reagent according to 
manufacturer’s protocol, and processed as described by Qiagen RNA clean-up protocol. 
For cell study, total RNA was extracted and genomic DNA contamination was removed 
using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), according to manufacturer 
protocol. Total RNA quality was assessed via RNA integrity gels and total RNA was 
quantified with a Nanodrop ND-1000 spectrophotometer. Total RNA was reverse-
transcribed to cDNA in a 10 µl reaction volume using a high capacity cDNA reverse 
transcription kit (Applied Biosystems). The reverse transcription (RT) master mix 
containing RT buffer, deoxyribonucleotide triphosphate (dNTP) mix, RT random primers, 
RNase inhibitor (1.0 U/µl), and MultiScribe RT was added to 1 µg RNA and RNase-free 
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water. Reverse transcription reaction conditions followed the protocol (25°C for 10 min, 
37°C for 120 min, 85°C for 5 sec, followed by 4°C in definitely/ RT complete) and utilized 
the Gene Amp PCR System 9700 thermal cycler (Applied Biosystems) for cDNA 
synthesis. 
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems) 
that consisted of enzyme activation at 95°C for 20 sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing /extension at 60°C for 30 sec. All 
data were analyzed with the ABI 7500 real time PCR system. All TaqMan primer probes 
used in this study were also purchased from ABI. Data were recorded and analyzed with 
ABI Sequence Detector Software and graphs visualized with SigmaPlot software. All 
data were presented as mean ± standard error of the mean (SEM) and representative of 
duplicate determinations. Data were normalized to 18S and measured as relative 
differences using the 2-∆∆CT method as previously described (35,36).  
Statistical analyses were conducted using SPSS v18. Differences in gene 
expression between lean and obese animals as well as between PAs and ADs were 
determined via student’s t-test where a p-value of <0.05 was considered significant. 
Other data were analyzed using analysis of variance (ANOVA), with Tukey's post-
hoc analysis used when the p-value for the respective parameter was statistically 
significant (p < 0.05). 
 ELISA. PAs and ADs were treated with or without TNFα (100 pM) and LPS (100 
ng/ml) for 12, 24, and 36 hrs. Supernatants were collected and subjected to sandwich 
ELISA. Cytokine (IL-12p70 and IL-27p28) levels in tissue culture media were determined 
by sandwich ELISA as described by the manufacturer (R & D systems). Cytokine IL-23 
(p19/p40) levels in tissue culture media were determined by sandwich ELISA as 
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described by the manufacturer (Biolegend). Optical densities were determined using a 
PowerWave microplate spectrophotometer (BioTek) at 450 nm. For the wavelength 
correction, 570 nm was used for correction for optical imperfections in the plate. Data 
were analyzed using a four parameter logistic (4-PL) curve-fit. Cytokine concentrations 
in media were determined from standards containing known concentrations of the 
proteins.  
 
Results 
Relative IL-12 family cytokine and receptor gene expression across insulin 
responsive tissues from lean C57BL/6J mice.  As recent evidence has demonstrated 
a potential role for IL-12 family cytokines in obesity-induced IR (13,14), we began these 
studies by determining the gene expression profile across four major insulin responsive 
tissues including white adipose tissue (WAT), liver, skeletal muscle and heart isolated 
from 10 wk old lean C57BL/6J mice where cytokine and receptor mRNA abundance was 
normalized to 18S rRNA and expressed as fold-differences relative to WAT. As 
illustrated in Fig.2.2, all cytokine and receptor subunits were expressed most abundantly 
in WAT with the exception of p35 that was ~90-fold more abundant in skeletal muscle 
and IL-12Rβ1 that was ~3-fold more abundant in liver. Surprisingly similar patterns of 
tissue distribution were noted for several genes including EBI3, p40, p19, WSX-1 where 
relative mRNA was most abundant in WAT and least abundant in skeletal muscle as well 
as IL-12Rβ2 and IL-23R that were markedly more abundant in WAT relative to all other 
tissues examined.   
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Relative IL-12 family cytokine and receptor gene expression within insulin-
responsive tissues comparing lean and obese Ob/Ob mice.  While IL-12 family 
cytokines are well established in critical roles during inflammatory stress involving 
antigen-presenting and other immune cells, the role of these cytokines regarding 
obesity-induced chronic, low-grade inflammation in metabolically active tissues remains 
poorly understood. Therefore, we next examined the impact of obesity on the expression 
of IL-12 family cytokines and receptors in each of the insulin-responsive tissues 
discussed above. For this study, we compared 10 wk old lean, wildtype mice and obese, 
leptin-deficient (ob/ob) mice given ad libitum access to standard chow. Using this genetic 
model of obesity, we determined relative mRNA abundance for each cytokine and 
receptor where obese values were expressed as fold-differences relative to lean within 
each tissue. As shown in Fig.2.3, WAT and skeletal muscle presented with similar 
profiles of gene expression where p28, EBI3 and p40 were significantly induced in obese 
relative to lean tissue. These data were particularly interesting as these two tissues are 
well established as critical mediators of obesity-induced inflammation. This is in striking 
contrast to heart tissue where the same three cytokine subunits and their cognate 
receptors were significantly suppressed with obesity. Although well established as an 
insulin-responsive tissue, there are no known reports demonstrating a role heart tissue 
in obesity-induced inflammation. As an important target of inflammatory cytokine action 
regarding insulin-sensitivity, it was also interesting to note that skeletal muscle presented 
with the greatest number of receptor subunits induced with obesity.    
Relative IL-12 family cytokine gene expression in WAT during the 
progressive development of genetic and diet-induced obesity. It is well recognized 
that WAT is a key site for obesity-induced inflammation leading to systemic IR (11,32). 
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As data presented above demonstrated that IL-12 family cytokines were abundantly 
expressed in WAT and induced with genetic obesity, we next examined the progression 
of obesity on IL-12 family cytokine expression in WAT using two distinct stages and 
models of obesity (genetic vs. diet-induced obesity). According to the supplier, ob/ob 
mice exhibit hyperplasia with ensuing obesity notable at 1 month of age and transient 
glucose intolerance that begins at ~6 wks of age and subsides between 12-16 wks of 
age. Thus, for comparison of progressive development, experiments were conducted 
with 6 wk and 10 wk old ob/ob mice and wildtype littermates, representing sequential, 
progressive stages of obesity with developing obesity-related metabolic disorders. For 
development of diet-induced obesity (DIO), C57BL/6J male mice were fed a high fat diet 
(HFD; 60% kcal from fat) by the supplier starting at 6 wks of age. Control littermates 
were fed a control diet containing 10% kcal from fat. Studies were conducted at 18 wks 
and 24 wks of age, representing 12 wks and 18 wks of dietary intervention, respectively. 
Progressive stages of obesity development in both models were arbitrarily designated as 
stage I and stage II. Using these models, we determined relative mRNA abundance for 
each IL-12 family cytokine as well as other well-characterized inflammatory cytokines in 
WAT where fold-differences were determined between lean and obese values at each 
stage of obesity development. Adipsin was included as a biochemical marker of obesity 
as others have documented a marked suppression of this gene in WAT of obese versus 
lean animals (37,38). 
As illustrated in Fig.2.4, mRNA expression of all IL-12 family cytokines showed 
no marked difference with stage I genetic (ob/ob) obesity. This was consistent with other 
inflammatory genes where TNFα and IL-6 were also not significantly different between 
lean and ob/ob mice at this stage of development. In contrast, however, relative mRNA 
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abundance of p28, EBI3, and p40 was significantly induced in stage II ob/ob mice, 
paralleling the induction of TNFα and IL-6 mRNA expression. Although not apparent as 
illustrated, adipsin mRNA abundance progressively decreased as ob/ob mice 
transitioned from stage I (40-fold reduction) to stage II (80-fold reduction) obesity. 
Regarding DIO, EBI3 and p40 were significantly induced after 12 wks of HFD (stage I), 
concomitant with induction of IL-6 and TNFα. Similar to stage II genetic obesity, relative 
mRNA abundance of p28, EBI3, and p40 was significantly elevated after 18 wks of HFD 
(stage II). Consistent with the progressive increase in IL-12 family expression, TNFα 
expression progressively increased (3-fold vs. 6-fold) and adipsin expression 
progressively decreased (7-fold vs. 25-fold) with progressive DIO. Collectively, these 
data demonstrated that gene expression of several IL-12 family cytokine subunits are 
induced at the level of gene expression in WAT based on the progressive stage of 
obesity development as well as the progressive inflammatory environment associated 
with sequential stages of obesity development.  
Relative IL-12 family cytokine and receptor gene expression in 3T3-L1 
adipocytes comparing undifferentiated preadipocyte (PA) and mature adipocyte 
(AD) mRNA abundance. The progression of obesity involves enlargement of adipose 
tissue mass through an increase in size and number of adipocytes as well as recruitment 
of macrophages that contribute to systemic circulating inflammatory cytokines originating 
from adipose tissue. To investigate a potential role for adipocytes in IL-12 family gene 
expression as observed above for WAT, we next examined relative mRNA abundance 
for each cytokine and receptor in 3T3-L1 murine adipocytes where values observed in 
mature, differentiated adipocytes (AD) were expressed as fold-differences relative to 
fibroblast-like, undifferentiated preadipocytes (PA). Both cell populations were rendered 
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quiescent either by density arrest as was the case for PAs or terminal growth arrest 
following 8 days of differentiation in ADs minimizing any influence of cell proliferation 
gene expression. As shown in Fig.2.5, differentiation had dramatic and opposite effects 
on the relative mRNA abundance of p28 and EBI3, where p28 mRNA was markedly 
more abundant and EBI3 markedly less abundant in ADs compared to PAs. 
Interestingly, p28 was the only gene of the IL-12 family cytokine and receptor subunits 
examined that increased with differentiation. More to this point, differentiation actually 
presented with a decrease in mRNA of WSX-1 and gp130 as well as IL-12Rβ1 and IL-
23R, the receptor subunits of IL-27 and IL-23, respectively, suggesting the possibility 
that PAs may be more susceptible than ADs to IL-12 family cytokines stimulation.  
Relative IL-12 family cytokine gene expression in PAs and ADs under 
conditions of inflammatory stress. As we observed a greater impact of obesity 
progression on IL-12 cytokine relative to receptor gene expression in WAT (Fig.2.3), we 
next determined the impact of inflammatory stress on relative IL-12 cytokine mRNA 
abundance in PAs and ADs as described above. For these determinations, total RNA 
was initially harvested from cells over time following stimulated with either 100 pM TNFα 
or 100 ng/ml LPS to determine the time of peak mRNA induction (not shown). This was 
followed by harvesting total RNA at times of peak induction following stimulation with 
TNFα or LPS or the combination of these two potent inflammatory mediators. Relative 
mRNA abundance was determined for each cytokine where the impact of each agonist 
was expressed as fold-differences relative to untreated (UT) controls. As illustrated in 
Fig.2.6, stimulation with TNFα or LPS markedly increased the mRNA abundance of all 
five IL-12 family cytokine subunits in a surprisingly similar pattern between PAs and ADs 
with one exception. While p28 mRNA increased nearly 500-fold when stimulated with 
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both TNFα and LPS in PAs, the same inflammatory agonists elicited only a 5-fold 
increase in mRNA in ADs. This observation is particularly interesting as we 
demonstrated above that p28 mRNA was elevated in ADs compared to PAs suggesting 
that this cytokine subunit becomes refractory to inflammatory stimuli with differentiation. 
These determinations also demonstrated a markedly synergistic effect of both 
inflammatory mediators in combination with the exception of EBI3 and p35 where TNFα 
stimulation alone was nearly equivalent to stimulation with both TNFα and LPS.  
Accumulation of IL-12 family cytokines in culture media of PAs and ADs 
under conditions of inflammatory stress. As inflammatory stimuli elevated the mRNA 
abundance of all five IL-12 family cytokine subunit genes, we next assessed the impact 
of inflammatory stress on the protein accumulation of IL-12, IL-23, and IL-27 in the 
culture media by ELISA. As functionality of these cytokines depends on heterodimeric 
partnering of specific alpha and beta chain subunits, ELISAs measuring both proteins 
were used for IL-12 and IL-23. As this co-detection technique was not commercially 
available for IL-27, ELISA measuring only p28 protein was utilized instead. As shown in 
Fig.2.7, IL-27 as measured by p28 protein detection accumulated in the culture media in 
a time-dependent manner following stimulation with TNFα and LPS. As others have 
demonstrated that secretion is dependent on prior dimer formation, these data likely 
represented secretion of functional IL-27 protein comprised of p28 and EBI3 
heterodimers. Neither IL-12 nor IL-23 was detected in the culture media over a 36 hr 
period following inflammatory insult.  
Effect of IL-27 stimulation on inflammatory signaling pathways. As we 
demonstrated that IL-27 receptor subunit mRNA was more abundant in PAs than ADs 
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(Fig.2.5), we next determine the effect of IL-27 stimulation on signaling pathways that 
are known to be regulated by this cytokine. For these determinations, cell lysates were 
collected over time from PAs stimulated with 50 nM IL-27 and immunoblotted for 
phosphorylated and activated forms of STAT and MAPK proteins as well as the 
degradation of IκBα as an indirect indicator of NF-κB signaling. As illustrated in Fig.2.8, 
IL-27 stimulation resulted in transient accumulation of p-ERK, p-JNK, and p-STAT3 with 
peak accumulation at 15, 30, and 60 mins, respectively. Phosphorylation of STAT1 and 
p38 was not detected and a minimal decrease in IκBα from IL-27 stimulation was 
observed. 
Effect of IL-27 stimulation on basal inflammatory gene expression. As we 
demonstrated above that IL-27 was capable of eliciting signaling pathways that link 
cytokine action to inflammatory gene expression, we next examine the effect of IL-27 
stimulation on basal inflammatory gene expression. Total RNA was extracted from cells 
over time following stimulation with 50 nM IL-27. Relative mRNA abundance at each 
successive time point was expressed as fold-differences relative to levels observed prior 
to stimulation (0 hr). As shown in Fig.2.9, IL-27 stimulation resulted in a decrease in 
mRNA abundance for each of four classic inflammatory genes of MCP-1, IL-6, COX-2, 
and TNFα. In each case, the effect was maximal within 3 hrs and was sustained 
throughout the 24hr period under study suggesting a potential anti-inflammatory role of 
IL-27 under these conditions. 
Effect of IL-27 stimulation on cytokine-mediated inflammatory gene 
expression. We next determined the effect of IL-27 stimulation on cytokine-mediate 
inflammatory gene expression with the same four genes examined above. Total RNA 
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was extracted from PAs at 2 hrs post-stimulation with 100 pM TNFα or 50 nM IL-27 or in 
combination. Relative mRNA abundance was determined for each cytokine where the 
impact of each agonist was expressed as fold-differences relative to untreated (UT) 
controls. As illustrated in Fig.2.10, TNFα elicited a marked increase in mRNA for all four 
inflammatory genes previously determined to peak at 2 hrs post-stimulation. While IL-27 
alone had no effect on gene expression, it markedly increased the effect of TNFα on 
mRNA accumulation suggesting a potential pro-inflammatory role of IL-27 under these 
conditions. 
 
Discussion 
In this study, we present the first empirical evidence that IL-12 family cytokines 
and their cognate receptors are divergently regulated in insulin responsive tissues under 
conditions of obesity. First, we report that all IL-12 family cytokines and cognate 
receptors are expressed well within detectable ranges in the insulin responsive tissues 
with most of this family of cytokines abundantly expressed in WAT. Second, we show 
that IL-27 is greatly regulated in WAT dependent on the developmental stage of obesity 
and the inflammatory progression associated with obesity. Third, our data demonstrate 
that among others, IL-27 is highly regulated and secreted from cultured adipocytes and 
plays an important role in regulating inflammation in adipocytes. Collectively, these data 
provide insight to possible roles of IL-12 cytokine family, particularly IL-27, in AT under 
conditions linking obesity with inflammatory diseases.  
Data presented in this study demonstrate the impact of obesity on the expression 
of IL-12 family cytokines in major insulin responsive tissues that play a critical role in 
65 
 
regulating metabolic homeostasis. Emerging studies highlight a role for select IL-12 
family cytokines in obesity-related diseases of several key insulin responsive tissues, 
supporting the tissue-specific roles of IL-12 family cytokines in mediating obesity-related 
inflammatory diseases and metabolic dysfunctions. For example, Li et al. have shown 
that up-regulation of IL-12 expression in liver of obese animals leads to alterations in 
hepatic immune system that consequently contribute to obesity-associated liver disease 
(39,40). Moreover, under conditions of obesity, levels of IL-12 have been shown to be 
associated with IR and increased AT inflammation (14-16,41,42). Data presented here 
also provide novel evidence of regulation of both cytokine and receptor by obesity in a 
tissue-specific manner. We show that elevated expression of IL-27 (i.e., p28 and EBI3) 
and IL-23 (i.e., p40 and p19) as well as their receptors (i.e., WSX-1, gp130, IL-12Rβ1, 
and IL-23R) in skeletal muscle with genetic obesity suggests a possible autocrine and/or 
paracrine role for these cytokines in skeletal muscle under conditions of obesity. Of the 
four tissues examined in this study, the heart was the only tissue that showed 
suppression of IL-27 genes with obesity. It has been reported that IL-27 has dual 
functions involved in pro- and anti-inflammatory processes (21,22,43). While the 
mechanisms underlying its anti-inflammatory properties are not yet clear, it has been 
observed that IL-27 suppresses several key inflammatory cytokines, such as TNFα, IL-6, 
and IL-17 (44-47). Suppression of IL-27 in heart with obesity, therefore, potentially 
exacerbates the inflammatory response by inhibiting IL-27 suppression of TNFα and IL-
6, two major players in vascular endothelial inflammation and atherosclerosis (48,49). 
Collectively, these data suggest a potential role of select IL-12 family cytokines in tissue-
specific regulation with obesity. 
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Recent studies demonstrate that one subunit of IL-27, p28 acts as a natural 
antagonist of gp130-mediated signaling (50), while others show that p28 and EBI3 are 
expressed independently in some cell types (51) and differentially regulated in response 
to various stimuli (52). Data presented here show that p35 was highly expressed in 
skeletal muscle, while either of its partners, (i.e., p40 or EBI3), were minimally expressed 
in the same tissue. However, p40 and EBI3 were induced with obesity in skeletal muscle 
while p35 expression was not affected by the same conditions. These data suggest that 
the p35 chain may have a function within this tissue independent of its regulatory 
capacity through IL-12 or IL-35. However, under conditions of obesity, p35 may bind with 
inducible p40 or EBI3 to form IL-12 or IL-35, respectively in skeletal muscle. These 
observations suggest that the individual subunits of IL-12 family cytokines play distinct 
functions in tissue-specific and condition-specific manners. While roles for individual IL-
12 family cytokine subunits have been studied in vitro, our in vivo data support 
observations that highlight the biological complexity regarding this cytokine family and 
remain to define their additional biological activities involved in metabolic inflammatory 
diseases.  
Chronic inflammation is an important element of pathogenic mechanisms linking 
obesity and metabolic diseases such as IR and type 2 diabetes. While various 
metabolically critical tissues are involved during the development of metabolic diseases, 
WAT is recognized as the predominant site for the secretion of inflammatory mediators 
that cause IR and systemic metabolic dysfunction (32,53). Moreover, numerous studies 
have shown that WAT inflammation is progressively developed during the course of 
obesity and the degree of obesity is positively associated with inflammatory state in WAT 
as macrophage infiltration into WAT gradually increases with the development of obesity 
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(54-57). To address correlations between WAT inflammation and the degree of obesity, 
we utilized expression patterns of three key inflammatory cytokines as well as adipsin as 
a biochemical maker for indicating degrees of obesity in WAT of two sequential stages 
(i.e., stage I and stage II) of genetic and diet-induced obese mice. Data from these 
studies demonstrate that MCP-1 was the earliest and only inflammatory maker elevated 
in stage I B6-ob/ob mice (6 wk old) while all three inflammatory markers (i.e., MCP-1, IL-
6, and TNFα) progressively increased when these mice reached stage II (10 wk old). 
These data also support those of other reports showing that MCP-1 expression is 
increased during initial stages of obesity to attract macrophages into WAT exacerbating 
the inflammatory process (53,56,58). Although mice fed a HFD show increased MCP-1, 
IL-6, and TNFα at both stages of development, the expression levels are progressively 
increased with sequential stages. These data collectively demonstrate that development 
of obesity is positively correlated with WAT inflammation that develops progressively 
over time.  
Data presented here demonstrate that several IL-12 family cytokines were 
abundantly expressed and divergently regulated in WAT based on stage of obesity and 
obesity-associated inflammation. Of the four cytokines, we show that IL-27 is 
significantly induced in WAT of stage II genetic- and diet-induced obese mice, paralleling 
the induction of key pro-inflammatory cytokines (i.e., TNFα, IL-6, and MCP-1). These 
findings suggest that IL-27 is involved in an advanced stage of obesity-induced 
inflammation in WAT that can modulate insulin sensitivity and glucose metabolism of this 
tissue. We also show up-regulation of p40, but not p35 expression in WAT with obesity 
where inflammatory genes IL-6, TNFα, and MCP-1 were elevated. Consistent with our 
findings, a recent study showed that DIO and ob/ob mice exhibited significantly 
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increased mRNA levels of p40 as well as IL-6 and TNFα in epididymal WAT, but no 
change was observed in p35 expression (41,59). We further report that expression of 
EBI3 and p40 as well as pro-inflammatory genes were elevated in stage I DIO, not ob/ob 
mice. These data suggest that HFD, containing high amount of saturated fat, triggers 
inflammation leading to upregulation of these genes in WAT as others have reported that 
high-fat feeding increased toll-like receptor signaling leading to inflammation in WAT 
(41,60). In contrast, p28 expression was only upregulated in stage II obesity in both 
animal model systems, suggesting that advanced stages of obesity may be responsible 
for elevated p28 gene expression in WAT. 
 As we demonstrate that of the four cytokines, IL-27 is highly induced in AT with 
obesity, we show unique regulation of this cytokine in cultured adipocytes. With 
adipocyte differentiation, p28 is up-regulated whereas its binding partner EBI3 is 
significantly down-regulated. Moreover, we report that both genes are highly induced 
with inflammatory stress in PAs and ADs with exception of p28 which shows refractory to 
the inflammatory stress with adipocyte differentiation. Importantly, IL-27, but not IL-12 
nor IL-23, is secreted from PAs and ADs in response to inflammation. These findings 
suggest that IL-27 potentially plays an important role in obesity-induced inflammation 
and adipocytes can be a major source for this cytokine to regulate this process. It is 
important to note that IL-12 and IL-23 secretion from adipocytes in culture media was 
undetectable using highly sensitive and specific ELISA even cells had been exposed to 
TNFα and LPS, despite the large increase in mRNA levels induced by these stimulations.  
 The interaction between the cytokine cascade networks operating within AT is an 
important mechanism mediating linking obesity to inflammatory diseases. It is evident 
that cellular cross-talk exists between adipocytes, preadipocytes, and macrophages (i.e., 
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resident and invading) in the tissue. These paracrine/autocrine interactions are a crucial 
factor in AT function. As we found secretion of IL-27 and expression of IL-27 receptors 
from both PAs and ADs, we hypothesized that IL-27 acts as an inflammatory mediator in 
adipocytes in a paracrine/autocrine manner. As IL-27 has been reported that it serves as 
two distinct functions for regulation of the immune responses (21,22), we showed two 
contrary functions of IL-27 on adipocytes based on conditions of inflammatory state. At 
the normal condition, IL-27 acts as an anti-inflammatory cytokine by reducing expression 
of a number of pro-inflammatory genes. In contrast, IL-27 functions as a pro-
inflammatory cytokine by exaggerating expression of the pro-inflammatory gene when 
we introduce pro-inflammatory environment by adding TNFα. Together, these findings 
suggest that IL-27 may play a protective role in obesity-associated inflammatory 
diseases. On the other hand, once AT gets inflamed, IL-27 exacerbates inflammation 
and negatively regulates AT metabolism and function.   
  In summary, this study provides the first comprehensive and systematic 
analysis of the IL-12 family cytokines under conditions of obesity in major insulin 
responsive tissues involved in metabolic homeostasis. Data presented here demonstrate 
that IL-12 family cytokines and receptors are divergently regulated in a tissue-specific 
manner under conditions of obesity. Moreover, the regulation of IL-27 cytokine in WAT is 
dependent on the developmental stage of obesity as well as the inflammatory 
progression associated with obesity. Our data further show that IL-27 is highly regulated 
and secreted from cultured adipocytes and plays an important role in regulating 
adipocyte inflammation. These data collectively suggest that divergent regulation of IL-
12 family cytokines, particularly IL-27 may contribute to the obesity-associated 
phenomenon of inflammation in metabolic tissues. 
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Figure 2.1. IL-12 family cytokines. IL-12 family cytokines are composed of shared 
alpha and beta chain subunits that dimerize to form IL-27, IL-35, IL-12, and IL-23. Each 
cytokine signals through unique heterodimeric cell surface receptors. Receptor 
composition for the newest member of the family, IL-35, has yet to be determined. 
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Figure 2.2.  Relative IL-12 family cytokine and receptor gene expression across 
insulin-responsive tissues from lean C57BL/6J mice.  Relative mRNA abundance of 
ligand (A) and receptor (B) subunits was determined by qRT-PCR from total RNA 
extracted from WAT, liver, skeletal muscle, and heart of 10 wk old lean C57BL/6J mice. 
Data were normalized to 18S rRNA and expressed as fold differences relative to WAT. 
Statistical differences were determined by ANOVA, with Tukey's post-hoc analysis 
performed when the p-value for the respective parameter was statistically significant (p < 
0.05). 
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Figure 2.3.  Relative IL-12 family cytokine and receptor gene expression within 
insulin-responsive tissues comparing lean and obese Ob/Ob mice. Relative mRNA 
abundance of ligand (A) and receptor (B) subunits was determined by qRT-PCR from 
total RNA extracted from WAT, liver, skeletal muscle and heart of 10 wk old lean and 
leptin-deficient (ob/ob) mice. Data were normalized to 18S rRNA and relative abundance 
determined for each cytokine and receptor where obese values were expressed as fold-
differences relative to lean within each tissue. Differences in gene expression between 
lean and obese animals were determined via student’s t-test where a p-value of <0.05 
was considered significant. 
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  Figure 2.4.  Relative IL-12 family cytokine gene expression in WAT during the 
progressive development of genetic and diet-induced obesity. Relative mRNA 
abundance of IL-12 family cytokine (A) and inflammatory genes (B) was determined by 
qRT-PCR from total RNA extracted from WAT at progressive stages of obesity from ob/ob 
mice as well as mice subject to DIO. Data were normalized to 18S rRNA and relative 
abundance determined for each cytokine where obese values were expressed as fold-
differences relative to lean within each group. Differences in gene expression between 
lean and obese animals were determined via student’s t-test where a p-value of <0.05 
was considered significant. 
74 
 
  
Figure 2.5.  Relative IL-12 family cytokine and receptor gene expression in 3T3-L1 
adipocytes comparing undifferentiated PA and mature AD mRNA abundance. Relative 
mRNA abundance was determined by qRT-PCR from total RNA extracted for undifferentiated 
3T3-L1 preadipocytes (PA) and mature 3T3-L1 adipocytes (AD). Data were normalized to 18S 
rRNA and relative abundance determined for each phenotype where AD values were 
expressed as fold-differences relative to PA. Differences in gene expression between cell 
phenotypes were determined via student’s t-test where a p-value of <0.05 was considered 
significant. 
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  Figure 2.6. Relative IL-12 family cytokine gene expression in PAs and ADs under 
conditions of inflammatory stress. Relative mRNA abundance of IL-12 family cytokines 
was determined by qRT-PCR from total RNA extracted for 3T3-L1 PA and AD at 2 hr or 12 hr 
post-stimulation with 100 pM TNFα, 100 ng/ml LPS, or in combination. Data were normalized 
to 18S rRNA and expressed as fold differences relative to untreated (UT) controls. Statistical 
differences were determined by ANOVA, with Tukey's post-hoc analysis performed when 
the p-value for the respective parameter was statistically significant (p < 0.05). 
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Figure 2.7.  Accumulation of IL-12 family cytokines in culture media of PAs 
and ADs under conditions of inflammatory stress. Concentration of IL-12, IL-23 
and IL-27 was determined by ELISA in cell media over time following TNFα (100 
pM) and LPS (100 ng/ml) stimulation of 3T3-L1 undifferentiated preadipocytes (PA) 
and mature adipocytes (AD). Values not detected (ND) were indicated.  
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Figure 2.8. Effect of IL-27 stimulation on inflammatory signaling 
pathways. Signaling pathways were evaluated by immunoblotting cell lysates 
collected from 3T3-L1 preadipocytes (PA) over time following 50 nM IL-27 
stimulation. TNFα (100 pM) and IFNγ (20 ng/ml) were included as positive 
controls for individual pathways. 
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Figure 2.9.  Effect of IL-27 stimulation on basal inflammatory gene expression. 
Relative mRNA abundance was determined by qRT-PCR over time for each inflammatory 
gene following 50 nM IL-27 stimulation of 3T3-L1 preadipocytes (PA). Data were normalized 
to 18S rRNA and relative abundance for each time point was expressed as fold-differences 
relative to levels observed prior to stimulation (0 hr).  
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 Figure 2.10. Effect of IL-27 stimulation on cytokine-mediated inflammatory gene 
expression. Relative mRNA abundance of specified inflammatory genes was determined by 
qRT-PCR from total RNA extracted from 3T3-L1 preadipocytes (PA) at 2 hrs post-stimulation 
with 100 pM TNFα or 50 nM IL-27 or in combination. Data were normalized to 18S rRNA and 
expressed as fold differences relative to untreated (UT) controls and IL-27 for TNFα 
stimulation and IL-27+TNFα stimulation, respectively. Statistical differences were determined 
by ANOVA, with Tukey's post-hoc analysis performed when the p-value for the respective 
parameter was statistically significant (p < 0.05). 
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CHAPTER III 
 
DIFFERENTIAL REGULATION OF IL-27 BY HISTONE DEACETYLASES DURING 
INFLAMMATORY STRESS IN ADIPOCYTES 
 
 
Abstract 
Chronic inflammation is an important element of pathogenic mechanisms linking obesity 
and diabetes. Interleukin-27 (IL-27) is a heterodimeric inflammatory cytokine encoded by 
independent p28 and EBI3 genes and plays a critical role in initiating and maintaining 
cell-mediated immune responses. Our previous investigations reported that IL-27 mRNA 
is significantly elevated in adipose tissue (AT) of genetic and diet-induced murine 
models of obesity. In addition, we have previously shown that cultured preadipocytes 
(PAs) and adipocytes (ADs) secrete IL-27 under conditions of inflammatory stress. In 
this study, we investigated the molecular mechanisms that regulate IL-27 in 3T3-L1 
adipocytes using TNFα as a model of inflammatory stress. We report here that IL-27 
genes were divergently regulated based on cell phenotype with p28 mRNA significantly 
more abundant in ADs compared to PAs and EBI3 mRNA significantly more abundant in 
PAs compared to ADs. We further report that TNFα resulted in marked induction of p28 
and EBI3 gene expression, but with different kinetics where mRNA abundance peaked 
at 4 hrs and 12 hrs, respectively. While similar kinetics of induction were observed for 
EBI3 in ADs, there was no marked induction in p28 expression at any given 
concentration of TNFα. Pharmacological inhibition of inflammatory signaling identified 
NF-κB as the predominant upstream activator of both p28 and EBI3. However, the 
divergent regulation of IL-27 within the same cell type as well as the refractory nature of 
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p28 in ADs was not due to differences in NF-κB signaling, as this pathway was similarly 
activated in PAs and ADs. As a plausible mechanism regarding differences in gene 
regulation, we further identified histone deacetylase (HDAC) activity was necessary for 
TNFα-induced p28 in PAs, but not ADs. Conversely, EBI3 expression in response to 
TNFα was completely independent with HDAC activity. Collectively, these findings 
suggest a role for HDACs in the divergent regulation of IL-27 gene expression in 
response to inflammatory stress and adipocyte differentiation.  
 
Introduction 
 Obesity is a major risk factor for cardiovascular disease, stroke, and type 2 
diabetes. Early studies have revealed an important role for AT in the regulation and 
control of whole-body metabolic homeostasis in normal and diseased states. 
Furthermore, evidence indicates that cellular and molecular mechanisms involved in AT 
metabolism are altered by obesity, leading to insulin resistance (IR) (1,2). It is now well-
established that chronic inflammation, originating in AT, is an important element of 
pathogenic mechanisms linking obesity and diabetes (3,4). Molecular mechanisms that 
underlie the initiation of AT inflammation during the onset of obesity include synthesis 
and secretion of various chemokines, such as monocyte chemoattractant protein-1 
(MCP-1), that enhance AT accumulation of macrophages leading to further inflammatory 
processes mediating IR (5). While it is now evident that chronic, low-grade inflammation 
is highly associated with obesity-induced inflammation and IR, key inflammatory 
mediators that contribute to this process have not been fully elucidated.  
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 IL-27 is a member of IL-12 family cytokines that play crucial roles during 
inflammatory processes. This cytokine is composed of two heterodimeric subunits (i.e., 
p28 and EBI3), and initiates its actions through binding to a heterodimeric cell-surface 
receptor composed of WSX-1 and gp130, where gp130 is required for both ligand 
binding and signal transduction (6). While early literature suggested that IL-27 
expression is restricted to myeloid cells including monocytes, monocyte-derived dendritic 
cells (DCs), and macrophages (7), more recent studies have also reported regulation of 
IL-27 in other, traditionally non-immune cell types. To this point, EBI3 and p28 have 
been shown to be expressed in trophoblasts throughout human pregnancy (8) and highly 
expressed in vascular smooth muscle cells and endothelial cells in response to pro-
inflammatory stimuli (i.e., TNFα or IFNγ) (9,10). Similarly, previous reports from our lab 
have demonstrated that IL-27 expression was higher in AT of genetic and diet-induced 
murine models of obesity and that IL-27 was secreted from cultured adipocytes under 
conditions of inflammatory stress. As evidence has established a mechanistic role for 
gp130 cytokines in obesity-induced IR (11-13), these findings support a role for IL-27 in 
the mechanisms linking excess nutrient intake to AT inflammation and IR.  
Activation of nuclear factor kappa B (NF-κB) signaling events by various 
inflammatory stimuli largely contribute to the transcriptional regulation of IL-27 in 
classical immune cells (14,15). NF-κB is a family of transcription factors composed of 
five subunits: p50, p52, p65 (RelA), p62 (RelB), and c-Rel, which form homodimers 
and/or heterodimers to regulate inflammatory gene expression. Canonically, NF-κB 
subunits are held in the cytosol under basal conditions and bounded a group of proteins 
known as inhibitors of NF-κB (IκBs). Upstream IκB kinases (IKKs) are activated by 
inflammatory stimuli leading to the phosphorylation and subsequent degradation of IκBs 
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and the release of NF-κB subunits that translocate to the nucleus where they act as a 
transcription factors to promote inflammatory gene expression (16,17). In addition to 
compartmental considerations, NF-κB transcriptional activity is dependent on post-
translational modifications, such as acetylation, that promote interaction with co-
activators and co-repressors (16,18,19). While co-activators, such as CREB binding 
protein (CBP) and the steroid receptor coactivator (SRC) family play an important role in 
activation of NF-κB mediated transcriptional activity (20-23), co-repressors, such as 
histone deacetylases (HDACs) and nuclear receptor corepressor (N-CoR) negatively 
regulate NF-κB dependent gene expression (23,24). In contrast to their inhibitory role in 
the transcriptional complex, recent reports have demonstrated that HDACs also promote 
NF-κB activity at multiple steps along the pathway that are critical for nuclear 
translocation and promoter interaction (25,26) as well as IκBα degradation (27). 
Accordingly, HDACs has been deemed anti-inflammatory as treatment with HDAC 
inhibitors negatively regulate NF-κB-dependent transcription by blocking translocation 
and DNA binding as well as interfering with RNA polymerase II recruitment (28,29).    
In the present study, we investigated the role of NF-κB signaling on epigenetic 
regulation of IL-27 in adipocytes in response to inflammation. We showed that divergent 
regulation of IL-27 genes, p28 and EBI3, involved HDAC-dependent and -independent 
mechanisms downstream of NF-κB signaling and that the refractory nature of p28 in ADs 
was not due to differences in upstream signaling pathways as they were similarly 
activated in PAs and ADs. Collectively, our findings support a regulatory role for HDACs 
that is both gene and cell-type specific, potentially contributing to the refractory nature of 
p28 as PAs mature into ADs as well as the exacerbated response of PAs to 
inflammatory stress. 
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Materials and Methods 
Materials. Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS), 
Trypsin-EDTA, and recombinant murine TNFα were purchased from Invitrogen. Fetal 
bovine serum (FBS) was obtained from HyClone. The following antibodies were used for 
immunoblot analysis: phospho-ERK (Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), 
phospho-JNK (Thr183/Tyr185), IκBα, phospho-IKKα (Ser176) /IKKβ (Ser 177), α-tubulin 
(Cell Signaling), NFκBp65 (Santa Cruz), Nucleoporin p62 (BD transduction). Trichostatin 
A (TSA), sodium butyrate (NaB), and nicotinamide (NAM) were obtained from Sigma. 
Pharmacological inhibitors of ERK (U0126), JNK (SP600125), p38 (SB203580) were 
purchased from CalBiochem. NF-κB inhibitor (helenalin) was obtained from Biomol. 
Enhanced chemiluminescence (ECL) reagents were obtained from Perkin-Elmer Life 
Sciences. All TaqMan primer probes used in this study were purchased from Applied 
Biosystems.  
Cell culture. The murine 3T3-L1 cell line was purchased from Howard Green, 
Harvard Medical School (30). Cells were propagated in DMEM supplemented with 10% 
CS until reaching density-induced arrest as previously described (31). At 2 days post-
confluence, growth medium was replaced with DMEM supplemented with 10% FBS, 
0.5mM 1-methy-3-isobutylxanthane, 1µM dexamethasone, and 1.7 µM insulin (MDI) for 
2 days. Subsequently, cells were cultured in DMEM supplemented only with 10% FBS 
over the following six days as PAs differentiated into mature ADs. Throughout the study, 
‘time 0’ refers to density arrested cells immediately before the addition of MDI to the 
culture medium. Experiments described herein were conducted in density-arrested day 0 
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(d0) PAs or day 8 (d8) ADs. All experiments were repeated 2-3 times to validate results 
and ensure reliability.  
Immunoblotting. Cell monolayers were washed with phosphate-buffer saline 
(PBS) and scraped into ice-cold lysis buffer containing 0.1 M Tris (pH 7.4), 150 mM 
NaCl, 10% sodium dodecyl sulfate (SDS), 1% Triton X, 0.5% Nonidet P-40 (NP40), 1 
mM EDTA, 1 mM EGTA. Phosphatase inhibitors (20 mM β-glycerophosphate, 10 mM 
sodium fluoride and 2 μM sodium orthovanadate) and protease inhibitors (0.3 µM 
aprotinin, 21 µM leupetin, 1 µM pepstatin, 50 µM phenanthroline, 0.5 µM 
phenylmethylsulfonyl fluoride) were added to lysis buffer immediately prior to cell 
harvest. Cell lysates were sonicated and centrifuged (13,000xg, 10 min, 4⁰C), and the 
supernatant transferred to a fresh tube. Protein content was determined by bicinchoninic 
acid (BCA) procedures according to manufacturer’s (Pierce, Rockford, IL) instructions. 
Equal amounts of whole cell lysate protein were separated by SDS-PAGE 
electrophoresis. Cell lysates were mixed with loading buffer containing 0.25 M Tris 
(pH6.8), 4% SDS, 10% glycerol, 0.01% bromophenol blue, and 10% dithiothreitol, then 
heated at 80⁰C for 5 min prior to electrophoresis. Proteins were resolved on SDS-
polyacylamide gel electrophoresis (PAGE) and transferred to polyvinylidene fluoride 
(PVDF) membranes (Millipore corp., Billerica, MA). After transfer, membranes were 
blocked with 4% milk and probed with indicated primary antibodies overnight at 4⁰C. 
Membranes were subsequently probed with horseradish peroxidase-conjugated 
secondary antibodies for 1h at room temperature. Membranes were immersed in ECL 
and data visualized by autoradiography using CL-XPosure film (Pierce).  
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Real-time qRT-PCR. Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen, Valencia, Ca), according to 
manufacturer’s protocol. Total RNA was quantified with a Nanodrop ND-1000 
spectrophotometer and reverse transcribed to cDNA in a 10 μl reaction volume using a 
high capacity cDNA reverse transcription kit (Applied Biosystems). The reverse 
transcription (RT) master mix containing RT buffer, deoxyribonucleotide triphosphate 
(dNTP) mix, RT random primers, RNase inhibitor (1.0 U/µl), and MultiScribe RT was 
added to 1 µg RNA and RNase-free water. Reverse transcription reaction conditions 
followed the protocol (25°C for 10 min, 37°C for 120 min, 85°C for 5 sec, followed by 4°C 
indefinitely/ RT complete) and utilized the Gene Amp PCR System 9700 thermal cycler 
(Applied Biosystems) for cDNA synthesis. 
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems, 
Inc.) that consisted of enzyme activation at 95°C for 20 sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing/extension at 60°C for 30 sec. All 
data were analyzed with the ABI 7500 real time PCR system. All TaqMan primer probes 
used in this study were also purchased from ABI. Data were recorded and analyzed with 
ABI Sequence Detector Software and graphs visualized with SigmaPlot software. All 
data were presented as mean ± standard error of the mean (SEM) and representative of 
duplicate determinations. Data were normalized to 18S and measured as relative 
differences using the 2-ΔΔCT method as previously described (32,33).  
Statistical analyses were conducted using SPSS v18. Phenotypic differences 
were determined via student's t-test where p-value of <0.05 was considered significant. 
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Inhibitor data were analyzed using analysis of variance, with Tukey’s post-hoc analysis 
conducted to assess differences from controls (TNFα) when p<0.05. 
Nuclear/cytosolic fractionation. Cell were washed with PBS and incubated with 
ice cold isotonic buffer containing 20 mM Tris, pH 7.4, 125 mM NaCl, 1 mM EGTA, 1 
mM EDTA, and 1mM MgCl2, for 10 min on ice. The buffer was supplemented with fleshly 
prepared 0.1% NP40, and phosphatase/protease inhibitors as described above. 
Following detergent solubilization, cytosolic fractions were collected from the cell 
monolayer and clarified by centrifugation (13,000xg, 5 min, 4°C). Intact nuclei were 
subsequently collected in PBS and gently pelleted by centrifugation (300xg, 3 min, 4°C). 
Nuclear proteins were extracted in ice cold buffer containing 20 mM Tri (pH 7.4), 1% 
Triton X, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA supplemented with 
protease/phosphatase inhibitors and frozen at -80°C. Nuclear fractions were 
subsequently thawed on ice, sonicated, passes through a 21 gauge needle to shear 
DNA, and clarified by centrifugation (13,000xg, 10 min,4°C).  
 
Results 
 Divergent expression of IL-27 between PAs and ADs in response to TNFα. 
We previously demonstrated that IL-27 was elevated in animal models of obesity with 
documented inflammation and that PAs and ADs secreted IL-27 protein in response to 
inflammatory stress. As PAs and ADs are responsive to inflammatory stress, we 
examined the effect of TNFα on the regulation of IL-27 in these functionally diverse cell 
types of adipocyte lineage. Phenotypic comparisons of IL-27 was determined using the 
3T3-L1 murine cell line that yielded quiescent, undifferentiated PAs prior to 
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differentiation and greater than 90% ADs following differentiation. Furthermore, this well-
established cell line is devoid of other cell types (e.g., macrophages) providing ideal 
conditions for cell type-specific analyses. As an initial screen, cells were differentiated for 
8 days to yield mature ADs and IL-27 mRNA expression compared to undifferentiated, 
density-arrested PAs of similar passage. As illustrated in Fig.3.1A, IL-27 subunit genes 
displayed phenotypic differences in expression where p28 mRNA was significantly 
elevated in ADs compared to PAs and, conversely, EBI3 mRNA was conversely 
elevated in PAs compared to ADs. Following this initial phenotypic comparison, PAs and 
ADs were stimulated concurrently with 100 pM TNFα and total RNA harvested over time 
to assess mRNA expression of IL-27 by qRT-PCR. This concentration of TNFα was 
selected as it closely approximates the concentration of TNFα in human and animal 
models of obesity and has been shown to suppress insulin signaling in culture (34,35). 
As illustrated in Fig.3.1B, IL-27 subunits, p28 and EBI3 were markedly induced in PAs 
following TNFα stimulation. Kinetically, p28 was rapidly induced (<4 hrs), while peak 
induction of EBI3 was relatively delayed (>12 hrs) following exposure to TNFα. In 
contrast, only EBI3 was induced in ADs in response to TNFα, with magnitude and 
duration of mRNA expression similar to that of PAs. While mRNA expression of p28 was 
‘refractory’ to TNFα stimulation in ADs, basal expression of p28 was significantly 
elevated (~60-fold) in ADs versus PAs (Fig.3.1A). To confirm that p28 was refractory to 
TNFα in ADs, PAs and ADs were stimulated in parallel with increasing concentrations of 
TNFα. Total RNA was harvested at 2 hrs post-TNFα stimulation and qRT-PCR used to 
assess p28 gene expression. As illustrated in Fig.3.1C, p28 mRNA expression increased 
in a concentration-dependent manner in PAs with an estimated ED50 of ~100pM, but 
remained unchanged in ADs even at TNF concentrations as high as 1000pM.  
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 Phenotypic differences between PAs and ADs regarding TNFα mediated 
changes in MAPK and NF-κB activity. Inflammatory activation of MAPK and NF-κB 
signaling pathways plays a central role in the pathogenesis of obesity-induced IR as well 
as IL-27 gene expression in immune-responsive cells (9,14,15,36-39). As data 
presented above demonstrate cell type specific regulation of p28 and EBI3 in response 
to TNFα (Fig.3.1A), we next assessed MAPK and NF-κB signaling in PAs and ADs in 
response to TNFα. To compare phenotypic differences, PAs and ADs were treated 
concurrently with TNFα and lysates harvested over time prior to immunoblotting with 
phosphospecific antibodies for JNK, ERK, and p38, where bisphosphorylation on both 
threonine and tyrosine residues is well documented as essential and sufficient for 
catalytic activity (40). Lysates were also immunoblotted for degradation of IκBα as an 
indirect measure of NF-κB nuclear translocation and activation (16). As shown in Fig.3.2, 
TNFα treatment resulted in transient activation of all three MAPKs in PAs, where robust 
phosphorylation was observed at 15 min with complete dephosphorylation by 60 min.  
TNFα stimulation also resulted in near complete IκBα degradation occurring with similar 
kinetics to that of MAPK phosphorylation in PAs. Conversely, the same concentration of 
TNFα produced markedly less magnitude, but sustained JNK and ERK phosphorylation 
with minimal activation of p38. While IκBα degradation occurred with similar magnitude 
and slight delay in ADs compared to PAs.  
NF-κB regulates p28 and EBI3 in PAs in response to TNFα. To elucidate 
signaling events regulating p28 and EBI3 gene expression, PAs were pretreated with 
specific, pharmacological inhibitors of ERK (10 μM U0126), JNK (20 μM SP600125), p38 
(10 μM SB203580), and NF-κB (10 μM Helenalin) for 30 min prior to 100 pM TNFα 
stimulation. Total RNA was harvested from PAs at 4hr and 18hr post-TNFα stimulation 
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corresponding to peak p28 and EBI3 expression. Changes in mRNA abundance were 
assessed by qRT-PCR and set relative to unstimulated controls. As illustrated in Fig.3.3, 
inhibition of NF-κB signaling markedly and selectively suppressed TNFα-induced p28 
and EBI3 mRNA accumulation. As a measure of specificity, two other inflammatory 
genes, p19 and CCL2 were determined to be predominantly downstream of the MAPKs 
and not NF-κB using the same RNA preparation. Thus, these data clearly demonstrated 
that NF-κB represented a predominant signaling pathway regarding TNFα-induced 
changes in gene expression for both p28 and EBI3.  
 HDACs regulate TNFα-induced p28 gene expression, but not EBI3. Data 
presented above demonstrated that NF-κB signaling links TNFα action to p28 and EBI3 
gene expression. However, as p28 and EBI3 expression was divergently regulated, 
these data further suggested a potential for epigenetics in the diverse outcomes 
observed with IL-27 regulation. Since acetylation has been linked to NF-κB activity in 
other reports, we investigated the impact of several broad-spectrum HDAC inhibitors on 
the regulation of p28 and EBI3 gene expression by TNFα. PAs were pretreated for 30 
mins with trichostatin A (TSA; inhibitor of all HDACs except for the sirtuins), sodium 
butyrate (NaB; inhibitor of class I and II HDACs), or nicotinamide (NAM; inhibitor of 
sirtuin class III HDACs (41) prior to stimulation with 100 pM TNFα. As illustrated in 
Fig.3.4, all three HDAC inhibitors attenuated TNFα-induced p28 gene expression with 
the greatest effect shown with TSA. In contrast, TNFα-induced EBI3 mRNA 
accumulation was not suppressed by TSA, NaB, or NAM, demonstrating that HDAC 
activity was required for TNFα-induced p28, but not EBI3 gene expression. 
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 Inhibitory effect of TSA on TNFα-induced p28 expression is independent of 
pretreatment time.  As these genes were induced with markedly different kinetics, we 
next investigated a role for prolonged TSA treatment in the regulation of p28 and EBI3 
gene expression. PAs were pretreated with TSA for 1 hr or 24 hr prior to total RNA 
collection at 2 hr and 12 hr post-TNFα stimulation. As illustrated in Fig.3.5A, TSA 
attenuated TNFα-induced expression of p28 independent of pretreatment time in PAs. In 
contrast, TSA did not suppress EBI3 expression at either pretreatment time confirming 
that TNFα-mediated p28 and EBI3 gene expression involved independent regulatory 
mechanisms. As p28 and EBI3 gene expression was divergently regulated based on cell 
phenotype, we also examined a role for HDACs on mRNA accumulation in ADs in the 
absence and presence of TNFα stimulation. ADs were pretreated with TSA for 1 hr or 24 
hr and total RNA collected at 2hr and 12 hr post-TNFα. Consistent with results shown 
above, elevated p28 gene expression induced by differentiation was completely 
refractory to TNFα stimulation. Moreover, extended TSA pretreatment had no effect on 
differentiation induced p28 gene expression, nor the refractory nature of p28 to TNFα 
imposed by differentiation. While TNFα-induced EBI3 expression in ADs was not 
blocked by 1 hr TSA pretreatment, longer exposure to TSA increased TNFα-induced 
EBI3 expression, suggesting that HDACs may serve as co-repressors of NF-κB actions 
on EBI3 gene expression in ADs, but not PAs.  
HDAC activity is not necessary for NF-κB signaling or nuclear 
translocation. As data presented above demonstrated that TSA suppressed TNFα 
induced p28 gene expression in PAs, we next examined the role of HDACs on TNFα 
induced changes in NF-κB signaling. PAs and ADs were pretreated with or without TSA 
for 1 hr and 24 hr and cell lysates collected 15 min post-TNFα stimulation. Lysates were 
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immunoblotted for IKKα/β phosphorylation as well as IκBα degradation as sequential 
events leading to NF-κB activation. As illustrated in Fig.3.6, TNFα increased IKKα/β 
phosphorylation as well as IκBα degradation in both PAs and ADs. Interestingly, TSA did 
not attenuate TNFα-induced IKKα/β phosphorylation or IκBα degradation suggesting that 
the regulatory role of HDACs regarding p28 gene expression occurred downstream of 
these initial events in NF-κB signaling. Therefore, we next examined the role of HDACs 
on NF-κB (p65) nuclear translocation. PAs and ADs were pretreated with or without TSA 
for 1 hr prior to TNFα stimulation. Nuclear and cytosolic extracts were harvested at 30 
min post-TNFα and immunoblotted for NF-κB (p65). To confirm efficiency of 
fractionation, lysates were also immunoblotted for nucleoporin and α-tubulin as markers 
of nuclear and cytosolic fractions, respectively. As illustrated in Fig.3.7, TNFα induced 
nuclear NF-κB (p65) translocation was not blocked by TSA pretreatment suggesting that 
HDACs play a role in TNFα-induced p28 gene expression downstream of NF-κB 
translocation either through DNA interaction or by direct effects of histone acetylation 
important for p28, but not EBI3 gene expression.  
 
Discussion 
In this study, we present evidence for divergent regulation of IL-27 by HDACs in 
adipocytes. First, we show that the IL-27 subunits are differentially regulated in response 
to TNFα. While EBI3 was similarly induced in both PAs and ADs while p28 was only 
induced in PAs. Second, we demonstrate that EBI3 and p28 represent downstream 
targets of NF-κB signaling. Third, we report that the refractory nature of p28 in ADs was 
not due to differences in upstream NF-κB signaling, as this pathway was similarly 
98 
 
activated in PAs and ADs. Finally, we show that TNFα-induced p28 was attenuated with 
HDAC inhibition, potentially resulting from direct effects on chromatin acetylation. As 
external inflammatory cues are known to regulate gene expression through alterations of 
the epigenome, our data collectively support an epigenetic role for HDACs in the 
divergent regulation of p28, but not EBI3, in response to inflammatory stress in PAs, but 
not ADs. 
 Studies have established a significant role for IL-27 in the host defense against 
microbial infections, consequently leading to extensive examination into the regulation of 
IL-27 in immune cells. However, mechanisms that govern the regulation of IL-27 in non-
immune cells have yet to be elucidated. Moreover, immune cell regulation of IL-27 has 
primarily focused on upstream activation by toll-like receptors (TLRs) (42,43). Data 
presented here demonstrate that both p28 and EBI3 are highly induced in adipocytes in 
response to TNFα. However, the kinetics of mRNA expression vary considerably 
between the two subunits suggesting that different mechanisms may be involved. 
Consistent with our data, others report that p28 and EBI3 kinetics were not coordinated 
within a given cell and that this differential mode of regulation was common among 
various cell types and tissues (43-45). These observations confirm that the individual 
subunits of IL-27 are differentially regulated in response to external cues, yet the 
detailed mechanisms for these divergent actions are still unclear.  
 Our data demonstrate that activation of NF-κB is the predominant signaling 
pathway that links TNFα to p28 and EBI3 gene expression in adipocytes. As TLR-
mediated transcriptional regulation of p28 and EBI3 has been investigated in murine 
macrophages and dendritic cells (14,15), promoter analyses revealed the presence of 
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conserved NF-κB binding sites responsible for transcriptional activation. Furthermore, 
genetic ablation of NF-κB highlighted EBI3 as a downstream target of NF-κB activation 
(14). This observation is consistent with other studies suggesting that activation of NF-
κB is required for EBI3 promoter activity, where mutations of NF-κB binding sites within 
the distal and proximal promoter markedly suppressed EBI3 activity (46,47). Similar to 
EBI3, NF-κB has been shown to enhance p28 promoter activity induced by LPS (15,36). 
Taken together, these data suggest that NF-κB binding is both necessary and sufficient 
for transcriptional activation of p28 and EBI3 expression in response to inflammatory 
stress. 
Emerging evidence indicates that post-translational modification of NF-κB (e.g., 
acetylation, phosphorylation) (16,48,49) as well as recruitment of transcriptional co-
activators and co-repressors is required for NF-κB transcriptional regulation of many 
inflammatory cytokines (18,23,50-52). As regulation of co-activators (e.g., HATs) and co-
repressors (e.g., HDACs) is cell-type and condition-specific (53-56),  post-translational 
modifications of the genome, or epigenetics, potentially provides one mechanism for the 
divergent biological outcomes observed with p28 and EBI3. Studies demonstrate that 
co-activator and co-repressor function is not universal, as these modulators of 
transcription can act in an opposing manner depending on cell-type and gene 
environments (57,58). HDACs are known co-repressors that function to deacetylate 
nucleosomal histones and alter chromatin in a manner that leads to gene repression. 
However, HDACs can deacetylate lysine residues on many proteins, including NF-κB 
(p65). Thus, HDACs can regulate NF-κB through deacetylation of regulatory elements 
within NF-κB-dependent inflammatory genes as well as post-translational modification of 
NF-κB proteins (59,60). Despite the general role for HDACs as transcriptional co-
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repressors, it has been proposed that HDACs are necessary for gene expression (61). 
For example, deacetylation of p65 by HDACs has been shown to enhance NF-κB 
binding to the promoter region of select NF-κB target genes (62,63). Indeed, treatment 
with pan-HDAC inhibitors that blocks all HDACs have been shown to both enhance and 
suppress gene expression (64). Not surprisingly, HDAC inhibitors can promote NF-κB 
activity by increasing p65 acetylation (21,22,65) and diametrically act in an anti-
inflammatory manner through the repression of inflammatory genes, demonstrating that 
HDAC activity is cell-type and environment specific (66-68). Consistent with this notion, 
we demonstrate that both p28 and EBI3 are downstream targets of NF-κB signaling and 
yet HDAC inhibition with TSA only ablated p28 gene expression. Taken together, these 
data suggest that divergent regulation of EBI3 and p28 gene expression may, in part, be 
under the control of epigenetic modifications of nucleosomal chromatin and not 
upstream NF-κB signaling.   
 Recent evidence further highlights HDACs in the regulation of adipogenesis (69-
71). Chatterjee et al. demonstrated that class II HDAC9, is significantly down-regulated 
during adipocyte differentiation. Gain- and loss-of-function studies further demonstrated 
that HDAC9 acts as a molecular switch to regulate adipogenic gene expression and 
differentiation (69). Moreover, reports have shown that treatment with pan-HDAC 
inhibitors block adipogenesis (72). Our findings demonstrated that p28 gene expression 
was elevated with adipocyte differentiation, while EBI3 was suppressed. In addition, p28 
expression was not induced with TNFα in ADs, nor suppressed in the presence of HDAC 
inhibition. However, TNFα-induced EBI3 gene expression was further exacerbated with 
HDAC inhibition.  Collectively, these data suggest that HDAC activity is necessary for 
TNFα-induced p28 gene expression in PAs, but not required in ADs. Conversely, HDAC 
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activity represses EBI3 expression during adipocyte differentiation and loss of HDAC 
repression enhances EBI3 gene expression in response to inflammation. Thus, 
epigenetic alterations of the IL-27 gene may explain the divergent outcomes observed in 
PAs and ADs.  
 In summary, this study provides convincing evidence for the epigenetic regulation 
of IL-27 under conditions of inflammatory stress and in response to adipocyte 
differentiation. Data presented here demonstrate that two subunits of IL-27 (p28 and 
EBI3) are differentially regulated in adipocytes in response to TNFα, even though both 
p28 and EBI3 were downstream of NF-κB. Thus, it appears that external inflammatory 
stress alters the network of chemical switches, in particular acetylation, within cells 
collectively known as the epigenome that allows for NF-κB binding and gene expression. 
Conclusions drawn from our data have led to the following model whereby HDACs 
regulate p28 gene expression in PAs but not ADs (Fig.3.8). In contrast, regulation of 
EBI3 from TNFα is independent of HDAC activity and cellular differentiation (Fig.3.8). 
These data highlight the potential role for epigenetics in IL-27 regulation and may lead to 
novel epigenetic therapies combating obesity-induced inflammation, IR and ensuing 
diabetes.  
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Figure 3.1. Phenotype difference in TNFα-induced IL-27 expression in PAs and ADs. 
(A) Relative mRNA abundance for p28 and EBI3 of PAs and ADs was measured using 
qRT-PCR. Data were normalized to 18S rRNA and expressed relative to PAs. Statistical 
significance was determined by Student's t-test (* p<0.05). (B) PAs and ADs were 
stimulated in parallel with 100 pM TNF and changes in mRNA abundance determined 
over time relative to unstimulated (0 hr) conditions. (C) PAs and ADs were stimulated in 
parallel with increasing concentrations of TNFα. Total RNA harvested at 2 hr post-TNFα 
stimulation and p28 mRNA abundance was determined relative to unstimulated cells (0 
pM). 
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Figure 3.2. Phenotypic differences in TNFα-stimulated MAPK and NF-κB 
signaling between PAs and ADs. Cell lysates were harvested from PAs and ADs 
over time following TNFα (100 pM) stimulation and immunoblotted for p-ERK, p-
JNK, p-p38 as well as IκBα degradation. Total p38 was included as a loading 
control. 
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Figure 3.3. NF-κB signaling regulates TNFα-induced p28 and EBI3 gene expression. PAs 
were pretreated for 1 hr with inhibitors for ERK (U0126, 10 μM), JNK (SP600125, 20 μM), p38 
(SB203850, 10 μM), or NF-κB (Helenalin, 30 μM) prior to TNFα stimulation. Total RNA was 
harvested at 2 hr or 18 hr post-TNFα and mRNA expression analyzed for p28, EBI3, p19, and 
CCL2. Data were normalized to 18S rRNA and expressed relative to untreated (UT) controls. 
Statistical significance was determined by ANOVA with Tukey's post-hoc analysis conducted 
to assess differences between treatment groups when p<0.05. Abbreviations used: TNFα (T), 
ERK (E), JNK (J), p38 (P), and NF-κB (N). 
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  Figure 3.4. Effect of HDAC inhibitors on TNFα-induced p28 and EBI3 gene 
expression. PAs were pretreated for 1 hr with HDAC inhibitors, TSA (0.5 μM), NaB 
(1 mM), or NAM (5 mM) prior to 100 pM TNFα stimulation. Total RNA was harvested 
at 2 hr and 12 hr post-TNFα stimulation and assessed for p28 and EBI3 mRNA 
expression via qRT-PCR, respectively. Data were normalized to 18S rRNA and 
expressed related to untreated (UT) controls. Statistical significance was determined 
by ANOVA with Tukey's post-hoc analysis conducted to assess differences between 
treatment groups when p<0.05. 
 
106 
 
 
 
  
Figure 3.5. Effects of TSA on TNFα-induced p28 and EBI3 gene expression are 
independent with exposure time. PAs (A) and ADs (B) were pretreated for 1 hr or 24 
hr in the presence of TSA (0.5 μM) prior to 100 pM TNFα stimulation. Total RNA was 
harvested at 2 hr or 12 hr post-TNFα stimulation and assessed for p28 and EBI3 
expression via qRT-PCR, respectively. Data were normalized to 18S rRNA and 
expressed relative to untreated controls. Statistical significance was determined by 
ANOVA with Tukey's post-hoc analysis conducted to assess differences between 
treatment groups when p<0.05. 
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Figure 3.6. TSA does not inhibit TNFα-induced NF-κB signaling pathway 
activation. PAs (A) and ADs (B) were pretreated for 1 hr or 24 hr in the 
presence of TSA (0.5 μM) prior to 100 pM TNFα stimulation. Cell lysates were 
harvested at 15 min post-TNFα stimulation and immunoblotted for p-IKK and 
IκBα degradation. α-tubulin was included as a loading control. 
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Figure 3.7. TSA does not block TNFα-induced NF-κB nuclear 
translocation.  Nuclear and cytosolic extracts were harvested from PAs (A) 
and ADs (B) at 30 min after TNFα stimulation in the absence and presence 
of TSA (0.5 μM) and immunoblotted for NF-κB(p65). α-tubulin and 
nucleoporin were used as markers of cytosolic and nuclear fractions, 
respectively. 
 
109 
 
 
 
 
Figure 3.8. Working model for regulation of p28 and EBI3 gene expression by 
HDACs. In PAs, EBI3 gene is expressed in response to TNFα directly through NF-κB 
signaling events independent of HDAC activity. In contrast, TNFα induced p28 gene 
expression is postulated to require specific HDAC activity that decreases during 
adipocyte differentiation resulting in the refractory nature of p28 regarding inflammatory 
stress in ADs.  
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CHAPTER IV 
 
NOVEL MECHANISMS OF GOLGI-MEDIATED TNFα-INDUCED INFLAMMATORY 
GENE EXPRESSION IN ADIPOCYTES 
 
 
Abstract 
Tumor necrosis factor (TNF) α is pleiotropic cytokine that links obesity and IR. TNFα 
binds cell surface receptors (TNFR1/2) on adipocytes subsequently activating 
inflammatory signaling cascades that alter adipocyte function and exacerbate the 
inflammatory response. Evidence suggests that the Golgi apparatus (GA) plays a crucial 
role in TNFα signaling through redistribution of TNFα receptors (TNFRs). Despite these 
implications, no study has addressed a role for the GA on TNFα action in adipocytes. To 
address this question, we stimulated 3T3-L1 murine adipocytes with TNFα in the 
presence of a well-characterized pharmacological GA inhibitor, brefeldin A (BFA). We 
report that BFA significantly ablated TNFα-induced inflammatory gene expression; 
effects did not occur in the presence of lipopolysaccharide (LPS) or interferon (IFN) γ 
suggesting that the anti-inflammatory actions of BFA were specific to TNFα. We further 
demonstrate that BFA blocked TNFR1 and TNFR2 cell-surface expression, suggesting 
that a regulatory role for the GA on TNFα signaling in the cell. While pre-treatment with 
BFA blocked TNFα-induced MAPK and NF-κB signaling in a manner consistent with the 
effects on gene expression, co-treatment with BFA ablated inflammatory gene 
expression with no measurable attenuation of MAPKs or NF-κB signaling. Collectively, 
these findings demonstrate that the GA is a critical regulator of TNFα-induced 
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inflammation in adipocytes and highlights a novel target for the potential treatment of 
obesity-associated AT inflammation. 
 
Introduction 
Chronic inflammation plays a central role in coupling obesity and insulin 
resistance (1-3). Mounting evidence demonstrates that increased adiposity, associated 
with obesity, often results in elevated cytokine and chemokine secretion from adipocytes 
leading to AT remodeling by infiltrating macrophages and other cells of the immune 
system (4). The result is an exacerbated inflammatory response and the development of 
local and systemic IR. Over two decades of evidence has clearly positioned, TNFα, front 
and foremost, as a significant contributor to this pathophysiological association. This 
pleiotropic cytokine, which is elevated in animal and human AT tissue during 
development of genetic and diet-induced obesity, is well documented to reduce insulin 
sensitivity in vivo and in vitro (5,6). Furthermore, TNFα ablation, by immunosorbent 
strategies or targeted gene deletion, dramatically reduces ensuing insulin resistance (7). 
As mediating mechanisms impinge on insulin signaling pathways in the cytosol as well 
as inflammatory gene expression in the nucleus, it is not unexpected that numerous 
processes have evolved to mitigate TNFα action under non-inflammatory conditions.   
TNFα action is transduced in adipocytes through two cell surface receptors 
known as TNFR1 (p55) and TNFR2 (p75) (8). Although TNFα can bind and signal 
through TNFR2, most of its activity regarding inflammatory gene expression and IR 
occurs through TNFR1 where ligand binding leads to internalization of the ligand-
receptor complex (9,10). While some TNFα mediated-events depend on internalization, 
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others are terminated as the receptor is recycled through recycling endosomes back to 
the membrane with degradation of the ligand by lysosomal activity. If not recycled or 
replaced, the outcome of internalization would be a decrease in surface receptor density 
leading to a decrease in TNFα sensitivity. A similar loss in TNFR on the surface occurs 
following enzymatic cleavage of membrane-bounded receptors by TACE resulting in 
truncated, non-functional, soluble receptors (i.e., sTNFR) that are known to play a role in 
dampening TNFα activity (11,12). Thus, vesicular trafficking of TNFR, either from the de 
novo synthesis in the endoplasmic reticulum (ER) or through recycling endosome is 
critical for TNFα action. To this point, others have also reported that TNFR1 is 
predominantly localized to Golgi apparatus (GA) in a perinuclear compartment as 
opposed to cell surface expression providing a means to curtail receptor sensitivity when 
TNFα action is not warranted. As this pool of TNFR1 has been shown to translocate to 
the surface upon TNFα stimulation, it has also been suggested that the Golgi pool 
serves a reservoir to increase cell surface receptor density when TNFα action is 
warranted (13). It has also been demonstrated that the cytoplasmic domain of the 
TNFR1 possess a Golgi-localization sequence (14,15), but how and under what 
conditions this localized trafficking occurs has yet to be determined. Furthermore, to date, 
Golgi-associated TNFR1 has been reported for only a few cell types suggesting the 
possibility of a cell-type, condition-specific phenomenon.  
As studies have clearly demonstrated the dynamic nature of TNFR1 surface 
expression influenced by receptor internalization as well as receptor shedding, vesicular 
trafficking, which may or may not involve Golgi activity, represents an important 
regulatory mechanism mediating TNFα action. Despite the critical importance of TNFα 
signaling in the etiology of obesity-induced IR, no information regarding a role for the GA 
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in regulating TNFα action in adipocytes has emerged. In this study, we present evidence 
demonstrating obligatory roles for the GA in mediating TNFα induced inflammatory gene 
expression in the adipocytes. Data are presented demonstrating a role for the GA in 
maintaining TNFR surface density as well as an unreported role for this perinuclear 
organelle on inflammatory gene expression that is independent of surface density or 
signaling pathways that mediate TNFα action. 
 
Materials and Methods 
Materials. Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS), 
Trypsin-EDTA, and recombinant murine TNFα were purchased from Invitrogen. Fetal 
bovine serum (FBS) was obtained from HyClone. The following antibodies were used for 
western blot analysis: Phospho-ERK (Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), 
phospho-JNK (Thr183/Tyr185), phospho-ATF2 (Thr69/71), phosphor-c-JUN (Ser63), 
IκBα, and α-tubulin (Cell Signaling). Brefeldin A (BFA), monensin (MNS), cycloheximide 
(CHX), and lipopolysaccharide (LPS) were obtained from Sigma. Mouse recombinant 
interferon (IFN) γ, mouse polyclonal anti-goat TNFR1, TNFR2, control IgG, and donkey 
anti-goat IgG (H+L) phycoerythrin-conjugated antibodies were obtained from R&D 
systems. Enhanced chemiluminescence (ECL) reagents were obtained from Perkin-
Elmer Life Sciences. All TaqMan primer probes used in this study were purchased from 
Applied Biosystems. 
Cell culture. The murine 3T3-L1 cell line was purchased from Howard Green, 
Harvard Medical School (16). Cells were propagated in DMEM supplemented with 10% 
CS until density-induced arrest, as previously described (17). At 2 days post-confluence, 
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growth medium was replaced with DMEM supplemented with 10% FBS, 0.5 mM 1-
methy-3-isobutylxanthane, 1 µM dexamethasone, and 1.7 µM insulin (MDI) for 2 days. 
Subsequently, cells were cultured in DMEM supplemented only with 10% FBS over the 
following six days as preadipocytes (PAs) differentiated into mature adipocytes (ADs). 
Throughout the study, ‘time 0’ refers to density arrested cells immediately before the 
addition of MDI to the culture medium. Experiments described herein were conducted in 
density-arrested PAs (d0) or mature ADs (d8) pretreated with 1 µM BFA, 30 µM MNS, or 
5 µM CHX in indicated time points then stimulated with 100 pM TNFα, 100 ng/ml LPS, or 
20 ng/ml IFNγ. All experiments were repeated 2-3 times to validate results and ensure 
reliability.  
Immunoblotting. Cell monolayers were washed with phosphate-buffer saline 
(PBS) and scraped into ice-cold lysis buffer containing 0.1 M Tris (pH 7.4), 150 mM 
NaCl, 10% sodium dodecyl sulfate (SDS), 1% Triton X, 0.5% Nonidet P-40 (NP40), 1 
mM EDTA, 1 mM EGTA. Phosphatase inhibitors (20 mM β-glycerophosphate, 10 mM 
sodium fluoride and 2 µM sodium orthovanadate) and protease inhibitors (0.3 µM 
aprotinin, 21 µM leupetin, 1 µM pepstatin, 50 µM phenanthroline, 0.5 µM 
phenylmethylsulfonyl fluoride) were added to lysis buffer immediately prior to cell 
harvest. Cell lysates were sonicated and centrifuged (13,000g, 10 min, 4⁰C), and the 
supernatant transferred to a fresh tube. Protein content was determined by bicinchoninic 
acid (BCA) procedures according to manufacturer’s (Pierce, Rockford, IL) instructions. 
Equal amounts of whole cell lysate protein were separated by SDS-PAGE 
electrophoresis. Cell lysates were mixed with loading buffer containing 0.25 M Tris (pH 
6.8), 4% SDS, 10% glycerol, 0.01% bromophenol blue, and 10% dithiothreitol, then 
heated at 80⁰C for 5 min prior to electrophoresis. Proteins were resolved on SDS-
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polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene fluoride 
(PVDF) membranes (Millipore corp., Billerica, MA). After transfer, membranes were 
blocked with 4% milk and probed with indicated primary antibodies overnight at 4⁰C. 
Membranes were subsequently probed with horseradish peroxidase-conjugated 
secondary antibodies for 1h at room temperature. Membranes were immersed in ECL 
and data visualized by autoradiography using CL-XPosure film (Pierce).  
Real-time qRT-PCR. Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), according to 
manufacturer protocol. Total RNA was quantified with a Nanodrop ND-1000 
spectrophotometer and reverse transcribed to cDNA in a 10 µl reaction volume using a 
high capacity cDNA reverse transcription kit (Applied Biosystems). The reverse 
transcription (RT) master mix containing RT buffer, deoxyribonucleotide triphosphate 
(dNTP) mix, RT random primers, RNase inhibitor (1.0 U/µl), and MultiScribe RT was 
added to 1 µg RNA and RNase-free water. Reverse transcription reaction conditions 
followed the protocol (25°C for 10 min, 37°C for 120  min, 85°C for 5 sec, followed by 4°C 
indefinitely/ RT complete) and utilized the Gene Amp PCR System 9700 thermal cycler 
(Applied Biosystems) for cDNA synthesis. 
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems, 
Inc.) that consisted of enzyme activation at 95°C for 20  sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing /extension at 60°C for 30 sec. All 
data were analyzed with the ABI 7500 real time PCR system. All TaqMan primer probes 
used in this study were also purchased from ABI. Data were recorded and analyzed with 
ABI Sequence Detector Software and graphs visualized with SigmaPlot software. All 
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data were presented as mean ± standard error of the mean (SEM) and representative of 
duplicate determinations. Data were normalized to 18S and measured as relative 
differences using the 2-∆∆CT method as previously described (18,19). Statistical analyses 
were conducted using SPSS v18. Data were analyzed using analysis of variance, with 
Tukey’s post-hoc analysis conducted to assess differences between treatment groups 
when p<0.05.  
Nuclear/cytosolic fractionation. Cell were washed with PBS and incubated with 
ice cold isotonic buffer containing 20 mM Tris, pH 7.4, 125 mM NaCl, 1 mM EGTA, 1 
mM EDTA, and 1mM MgCl2, for 10 min on ice. The buffer was supplemented with fleshly 
prepared 0.1% NP40, and phosphatase/protease inhibitors as described above. 
Following detergent solubilization, cytosolic fractions were collected from the cell 
monolayer and clarified by centrifugation (13,000 x g, 5 min, 4°C). Intact nuclei were 
subsequently collected in PBS and gently pelleted by centrifugation (300 x g, 3 min, 4°C) 
Nuclear proteins were extracted in ice cold buffer containing 20 mM Tri (pH 7.4), 1% 
Triton X, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA supplemented with 
phosphatase/protease inhibitors and frozen at -80°C. Nu clear fraction were 
subsequently thawed on ice, sonicated, passes through a 21 gauge needle to shear 
DNA, and clarified by centrifugation (13,000 x g, 10 min, 4°C).  
Flow cytometry. Cells were washed with PBS and incubated with Accutase 
(Millipore, Billerica, MA) for a min to allow cells to detach. Cells were collected into a 
fresh tube with ice cold staining buffer containing PBS, 2% BSA, and 0.1 % sodium 
azide. Cells were washed twice by centrifugation (300 x g, 5 min). Cells were incubated 
with Fc receptor blocker (BD Biosciences) on ice for 5 min then incubated with primary 
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antibodies on ice for 45 min. Cells were then washed twice by centrifugation (300 x g, 5 
min) and incubated with secondary antibody on ice for 30 min in the dark. Cells were 
then washed three times as described above and re-suspended in 1 ml of the staining 
buffer for flow cytometric analysis using Guava easyCyte (Millipore). Data were analyzed 
using InCyte analysis software (Millipore).    
 
Results 
Identification of direct targets involving TNFα-induced inflammatory gene 
expression. As the GA is well-documented to play an obligatory role in protein secretion, 
we began these studies by screening for TNFα-induced inflammatory genes expression 
where mRNA accumulation was both rapid and independent of protein synthesis. This 
rationale was based on prior observations that TNFα-sensitive gene targets include a 
subset of genes whose mRNAs accumulate with delayed kinetics consistent with an 
‘indirect’ mechanism requiring synthesis and secretion of TNFα-inducible intermediate 
transcriptional modulators that regulate gene expression in an autocrine/paracrine 
manner. Therefore, excluding indirect targets would highlight novel roles for the GA that 
were independent of protein secretion. We conducted this screen with density-arrested 
3T3-L1 preadipocytes (PA) by harvesting total RNA over time following stimulation with 
100 pM TNFα. Changes in mRNA abundance were determined by qRT-PCR where data 
were normalized to 18S ribosomal RNA (rRNA) and expressed as fold differences 
relative to untreated (UT) controls. Examples of the kinetic screen were illustrated in 
Fig.4.1 where relative mRNA abundance of two cytokine (p28, EBI3) and two chemokine 
(CCL2, CCL5) genes were presented where panel A illustrates rapid genes with peak 
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induction occurring at 4 hrs and panel B showing delayed genes with peak induction at 
12 hrs post-TNFα stimulation.  
To determine a role for protein synthesis, PAs were pretreated with 5 µM 
cycloheximide (CHX) for 1 hr prior to stimulating with 100 pM TNFα. Total RNA was 
harvested at 2 hrs post-stimulation and changes in mRNA abundance determined 
relative to untreated controls. Total RNA was harvested at a time earlier than peak 
induction for either group of genes as longer exposures of TNFα in the presence of CHX 
are well documented to synergistically amplify the effects on cell toxicity (20,21). As 
depicted in Fig.4.2, inhibition of protein synthesis suppressed TNFα induced expression 
only for CCL5 whose mRNA was shown above to peak at 12 hrs post-stimulation 
suggesting the possibility that an indirect mechanism involving secretion of a 
transcriptional modulator. EBI3 was not examined in this experiment as the 2 hr time 
point was insufficient for significant mRNA accumulation. In contrast to CCL5, p28 and 
CCL2 were rapidly induced and independent of protein synthesis suggesting that both 
genes represented direct targets of TNFα action and unlikely to involve protein secretion 
as a component of gene expression.  
Pharmacological inhibition of GA activity ablates mRNA accumulation of 
TNFα-induced early and late gene expression. To determine a role for the GA in 
TNFα-induced gene expression, we initially used the fungal metabolite, brefeldin A (BFA) 
which is well-documented as having unusual specificity toward blocking guanine 
nucleotide exchange factors that are required for the recruitment of coat proteins that 
form the structural lattice that directs the formation and trafficking of vesicles that 
transport cargo through the GA (22-24). As exposure to BFA has been shown to result in 
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rapid collapse of the GA, this metabolite has been commonly used as an inhibitor of GA-
mediated protein secretion. For these experiments, PAs were pretreated with 1 µM BFA 
for 1 hr prior to stimulating with 100 pM TNFα. Total RNA was harvested at 2 hrs and 12 
hrs post-stimulation and changes in mRNA abundance determined relative to untreated 
controls. As illustrated in Fig.4.3, BFA ablated TNFα induced expression of both early (A) 
and delayed (B) genes as determined above. While these results were predicted for 
delayed genes that were dependent on protein synthesis and, presumably, the secretion 
of an indirect modulator of TNFα action, the near complete ablation of early TNFα 
inducible genes was unexpected. As early expressed genes were independent of protein 
synthesis, these data suggested that the inhibitory effects of BFA likely included 
mechanisms beyond the well-documented effects on secretory pathways.  
To confirm that the unexpected effects of BFA observed above were not gene or 
phenotype specific, experiments were conducted using undifferentiated PAs as well as 
differentiated adipocytes (ADs) that display structural and functional differences in 
phenotype and gene expression.  Both cell populations, representing the extremes of the 
adipocyte lineage, were pretreated in parallel with BFA for 1 hr prior to TNFα stimulation. 
Total RNA was harvested at 2 hrs post-stimulation and changes in mRNA abundance 
determined relative to untreated controls for only early expressed gene. As illustrated in 
Fig.4.4, BFA ablated TNFα-induced expression of cytokines (TNFα, IL-6), chemokines 
(CCL2, CCL3, CCL20) and other inflammatory modulators (e.g., Cox-2) independent of 
cell phenotype. To date, we have not identified any TNFα-sensitive inflammatory genes, 
early or delayed, whose expression is not ablated by BFA suggesting the possibility of a 
mechanism involving either the receptor or early signaling events that are common to all 
inflammatory genes that are induced through TNFα action. 
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Inhibition of GA activity has no effect on mRNA accumulation of LPS or 
IFNγ induced inflammatory gene expression. As experiments described above 
demonstrated that most, if not all, TNFα induced gene expression was dependent on GA 
activity, we next explored the effects of BFA on lipopolysaccharide (LPS) and interferon 
gamma (IFNγ) induced inflammatory gene expression as both modulators of 
inflammation are known to activate different cell surface receptors and utilize signaling 
pathways that are unique from TNFα. For these determinations, PAs were pretreated 
with BFA for 1 hr prior to LPS (100 ng/ml) or IFNγ (20 ng/ml) stimulation. Total RNA was 
harvested at 2 hrs post-stimulation and changes in mRNA abundance determined 
relative to untreated controls. As illustrated in Fig.4.5, LPS (panel A) as well as IFNγ 
(panel B) induced inflammatory genes displayed no effect of BFA pretreatment 
supporting the working hypothesis that GA activity was necessary for upstream events 
regarding TNFα induced gene expression. Furthermore, the absence of any measurable 
effect of BFA on LPS or INFγ induced genes suggested that the mechanism of action 
was not likely to include effects of cell toxicity. Lastly, these observations demonstrated 
that the mechanism responsible for the BFA effect did not include inhibition of general 
transcriptional machinery (e.g., RNA Pol II).  
Nanomolar BFA concentrations reversibly inhibit TNFα-induced 
inflammatory gene expression. To further support a specific role for BFA on GA 
activity, we determined the 50% inhibitory concentration (IC50) as well as the 
reversibility regarding TNFα-induced inflammatory gene expression. Others have shown 
that nanomolar concentrations of BFA result in dispersal of GA vesicle-associated coat 
proteins into the cytosol within minutes of exposure and that this process is reversible 
leading to re-association of coat proteins to GA vesicles as well as reformation of GA 
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structure and function within hours following removal of BFA from cell media (25-28). To 
estimate the IC50, PAs were pretreated with increasing concentrations of BFA for 1 hr 
prior to TNFα stimulation. Total RNA was harvested at 2 hrs post-stimulation and 
changes in mRNA abundance determined relative to untreated controls. As illustrated in 
Fig.4.6A, TNFα induced p28 gene expression was suppressed by BFA in a 
concentration-dependent manner with an estimated IC50 of ~100nM which is consistent 
with concentrations that have been shown to result in dispersal coat proteins into the 
cytosol and ensuing collapse of the GA. To determine the reversibility of this effect on 
gene expression, PAs were pretreated with BFA for 2 hrs prior to a washout period in 
which BFA was either left on the cells or removed by changing culture media. Cells were 
then maintained for 2 hrs under conditions of the washout phase (i.e., with or without 
BFA) prior to TNFα stimulation. Total RNA was harvested at 2 hrs post-stimulation and 
changes in mRNA abundance determined relative to untreated controls. As illustrated in 
Fig.4.6B, washout of BFA completely reversed the near complete ablation of TNFα-
induced gene expression imposed by BFA. Collectively, these studies suggest that 
mechanisms by which BFA inhibited TNFα-induced inflammatory gene expression likely 
include specific effects stemming from vesicular coat protein dispersal leading to 
structural and functional collapse of the GA.  
BFA regulates TNFR cell surface expression. Studies described above 
demonstrating that BFA inhibited numerous TNFα inducible inflammatory genes with 
near equal potency suggested the possibility of an upstream mechanism. As BFA had 
no effect on LPS or IFNγ inducible genes, these observations further highlighted a role 
for the GA regarding TNFR. To address this premise, we examined TNFR1 and TNFR2 
expression on the plasma membrane by flow cytometric analysis over time following 
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exposure to BFA. As illustrated in Fig.4.7A, both receptors were expressed on the 
surface of PAs. Furthermore, BFA treatment decreased surface expression of both 
receptors in a time dependent manner. Quantification of mean fluorescence intensity 
(Fig.4.7B) further demonstrated a rapid decrease in TNFR2 surface density with a 
marked reduction observed as early as 15 min following exposure to BFA. While TNFR1 
surface expression also decrease with BFA, significant reduction was not observed until 
1 hr post-stimulation with no discernible decrease in surface expression noted at 15 min. 
BFA stimulation for 4 hr reduced surface expression of both receptors to levels that 
approximated the near ablation of surface density observed following 12 hr BFA 
exposure. Collectively, these data demonstrated that maintenance of TNFR1 and 
TNFR2 on the surface of the cell was dependent on GA activity and surface expression 
was nearly ablated within 4 hr of BFA stimulation suggesting rapid turnover of both 
receptors on the surface involved a functional GA. The rapidity of receptor turnover was 
further suggested as both receptors markedly decreased within 1 hr BFA exposure 
where TNFR2, but not TNFR1, decreased following BFA stimulation for as little as 15 
min. As both receptors decreased with time following BFA stimulation, these data further 
suggested that a decrease in receptor density on the cell surface could account, in part, 
for the inhibitory effects of BFA on early TNFα-inducible inflammatory gene expression. 
BFA regulates TNFα-induced MAPK and NF-κB signaling. As data presented 
above demonstrated an inhibitory effect of BFA on TNFR surface expression, we next 
examined the effect of BFA on two major signaling pathways that link receptor activity 
with TNFα inducible inflammatory gene expression. For these determinations, we 
examined the phosphorylation states of the mitogen protein kinases (MAPKs) ERK, JNK, 
and p38 on residues that are well documented as necessary and sufficient for activity as 
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well as the degradation IκBα as an indirect measure of NF-κB activation. To confirm the 
specificity of BFA, a structurally distinct pharmacological inhibitor of GA activity, 
monensin (MNS) was included. As illustrated in Fig.4.8A, TNFα stimulation in the 
absence of BFA resulted in robust phosphorylation of ERK, JNK and p38 as well as IκBα 
degradation measured as measured by immunoblotting at 15 min post-TNFα stimulation. 
While co-stimulation with both TNFα and BFA produced no discernible effects on each 
signaling pathway, BFA pretreatment for 1 hr or 12 hr suppressed TNFα stimulated 
MAPK and NF-κB signaling in a manner that closely approximated the effects of BFA of 
TNFR surface expression as demonstrated above. As TNFR1 surface expression did not 
decrease until 1 hr following BFA stimulation as shown above, the lack of effect of BFA 
as a co-treatment on signaling events further supported a role for GA in maintaining 
TNFR surface expression. The specificity of BFA was further confirmed where MNS 
produced nearly identical results as those obtained with BFA regarding each signaling 
pathway (Fig.4.8B). 
BFA co-stimulation ablates TNFα-induced gene expression. As we observed 
that co-stimulation of BFA did not suppress TNFα-activated signaling pathways or TNFR 
cell surface expression, we next determined the length of BFA pretreatment time 
necessary for suppression of TNFα induced gene expression.  PAs were pretreated with 
progressively longer pretreatment times ranging from co-stimulation (i.e., 0 min BFA 
pretreatment) through 1 hr pretreatment that was shown above to ablate TNFα-inducible 
gene expression. Cells were stimulated with TNFα and changes in mRNA abundance 
were determined relative to untreated controls. As illustrated in Fig.4.9A, shortening the 
time of BFA pretreatment to the point of co-stimulation produced no discernible 
difference from 1 hr pretreatment regarding the inhibitory effect on TNFα inducible TNFα 
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gene expression. As this observation was unexpected, the results were confirmed with 
MCP-1 and p28 (Fig.4.9B) where the effects of co-stimulation were identical to those 
obtained for 1 hr pretreatment. As prolonged BFA pretreatment (i.e., 12 hr) resulted in 
more dramatic attenuation of inflammatory gene expression compared to BFA co-
treatment, these data suggested that the effects of BFA on TNFR cell-surface 
expression could only account for part of the inhibitory actions attributed to BFA. As BFA 
co-stimulation dramatically suppressed TNFα-induced gene expression with absolutely 
no discernible effects on TNFR surface expression or signaling events, these data 
further highlighted the possibility of a second Golgi-mediated mechanism regulating 
TNFα-induced inflammatory gene expression downstream of both signaling pathways .   
BFA co-stimulation does not suppress signaling magnitude and duration. 
To confirm that BFA co-stimulation produced no effects on TNFα signaling events, 
lysates were harvested over time from PAs co-stimulated with BFA and TNFα 
immunoblotted for phosphorylated ERK, JNK, and p38 as well as IκBα degradation 
where data were compared to TNFα or BFA stimulation alone. These determinations 
were different from those presented above where the effects of different BFA 
pretreatment times on signaling events were measured at a single 15 min time point. As 
illustrated in Fig.4.10, TNFα rapidly and transiently lead to phosphorylation of all three 
MAPKs and IκBα degradation with maximum activation observed at 15 min and 
complete deactivation by 60 min post-TNFα treatment. Moreover, no discernible 
differences on MAPK or NF-κB signaling magnitude were observed with BFA co-
stimulation. While co-stimulation also produced no difference in duration of IκBα 
degradation, modest differences in duration of phosphorylation (i.e., activity) were noted 
for each MAPK.  While both magnitude and duration of MAPK signaling has been shown 
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to play a role in biological outcome, the modest differences observed here were unlikely 
to account for the near complete ablation of TNFα inducible gene expression following 
BFA co-stimulation.  
BFA co-stimulation does not block translocation and phosphorylation of 
trans-acting factors mediating TNFα-induced gene expression. Data presented 
above demonstrated that BFA co-stimulation significantly suppressed TNFα-induced 
inflammatory gene expression, but did not inhibit TNFR cell-surface expression or 
upstream signaling. Therefore, we next examined the effect of BFA on nuclear AP-1 
(ATF-2, c-Jun) and NF-κB (p65) transcription factors downstream of MAPK and NF-κB 
signaling. Cytosolic and nuclear extracts were fractionated from cells at 30 min post-
stimulation with BFA and/or TNFα. Optimal cell fractionation was confirmed by 
immunoblot analysis of nucleoporin and α-tubulin representing nuclear and cytosolic 
proteins, respectively. Cellular localization was determined for NF-κBp65 as well as 
phosphorylated ATF-2 and c-Jun as these transcription factors are known to play 
regulatory roles in TNFα-induced inflammatory gene expression (29-32). As illustrated in 
Fig.4.11, co-stimulation with BFA did not block TNFα-induced phosphorylation of ATF-2 
or c-Jun or blunt nuclear translocation of NF-κBp65. As both measures are indirect 
indices of activity, these data suggest the mechanism ascribed to the inhibitory effects of 
BFA co-stimulation on TNFα inducible inflammatory gene expression is likely to involve 
other modulators of transcription such as co-activator recruitment as opposed to direct 
effects on mediating transcription factors.  
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Discussion 
We present empirical evidence demonstrating novel roles for the GA in mediating 
TNFα-induced inflammatory gene expression in adipocytes. First, we show that the Golgi 
specific inhibitor, BFA ablated TNFα-induced inflammatory gene expression independent 
of secretory mechanisms requiring protein synthesis and that this inhibition was specific 
to TNFα. Second, we report that BFA blocked TNFR1 and TNFR2 cell-surface 
expression contributing to a decrease in MAPK and NF-κB signaling and subsequent 
gene expression. Third, we report that co-stimulation of BFA with TNFα was sufficient to 
ablate inflammatory gene expression, independent of TNFR cell-surface expression as 
well as TNFα signaling pathways. Fourth, we present evidence that TNFα-induced NF-
κBp65 and AP-1 nuclear translocation and phosphorylation were not inhibited by BFA 
co-stimulation. Collectively, data presented in this report suggest that the Golgi plays 
diverse regulatory roles in mediating TNFα-induced inflammatory gene expression in 
adipocytes through mechanisms dependent on and independent of TNFR cell-surface 
expression as well as TNFα signaling.  
 Early findings demonstrated that TNFα was elevated in AT of obese animals and 
humans and that genetic and pharmacological ablation of this pleiotropic cytokine 
improved insulin sensitivity (1,6). Within adipocytes, TNFα binds to TNFR triggering a 
cascade of events that activate MAPK and NF-κB signaling culminating in IR through 
inhibitory phosphorylation of IRS-1 in the cytosol as well as activation of inflammatory 
gene expression in the nucleus (33-37). In other cell types, studies have shown that 
upon ligand binding, the ligand-receptor complex is internalized in clathrin-coated 
vesicles that shuttle the ligand to lysosome for degradation and the receptor back to the 
133 
 
membrane via recycling endosomes (13,38). Others have also reported on the dynamic 
nature of TNFR on the cell surface as membrane-anchored receptors are enzymatically 
cleaved by the sheddase, TACE and released into the local milieu (39-41). While there is 
considerable evidence supporting the dynamic turnover of TNFR on the cell surface, it 
remains unclear what role, if any, the GA plays in TNFR cell surface expression or TNFα 
activity in adipocytes.  
 Extensive studies highlight a critical role for the GA in the post-translational 
modification and distribution of proteins and lipids to the cell surface or to other locations 
within the cell. Proteins or lipids enter the GA from the ER where they can be modified 
through glycosylation, phosphorylation, methylation, or acetylation (42-44) prior to being 
directed to their final destination inside or outside of the cell (45). Indeed, most studies in 
adipocytes have focused on the role for the GA in trafficking glucose transporter, GLUT4 
to the plasma membrane in response to insulin signaling (46,47). While there is growing 
evidence that the GA plays an additional role in compartmentalizing signaling cascades 
that originated at the plasma membrane (48), no studies have examined a role for the 
GA in TNFR trafficking or a role for of the GA in TNFα-induced signaling pathways and 
inflammatory gene expression in adipocytes.  
 This report is the first study to show that inhibition of the Golgi complex ablates 
TNFR cell-surface expression in adipocytes. Emerging evidence has demonstrated that 
TNFR1 localizes to the GA to serve as a reservoir in regulating cell-surface expression 
in endothelial and smooth muscle cells (13,15,38). Although we have yet to determine 
the precise cellular localization of TNFR under basal states as well as under conditions 
of inflammatory stress, we clearly demonstrate in this report that TNFR1 and TNRF2 are 
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expressed to some degree on the cell surface functionally coupling TNFα action to 
MAPK and NF-κB signaling pathways and  inflammatory gene expression. Our data also 
demonstrate that the expression of both receptors on the surface of the cell is a dynamic 
process highlighting a role the GA in maintaining surface density. While the precise 
mechanism is currently under investigation, it is plausible that 1) the GA may serve as a 
reservoir for TNFR1 in adipocytes as has been shown for endothelial cells (13), 2) 
endocytic recycling of internalized TNFR back to the membrane that may involve 
essential processing of vesicle cargo by the GA, and 3) surface expression requires de 
novo TNFR synthesis where the GA may play a role in trafficking of the receptor from 
the ER to the plasma membrane. As the collapse of the GA with BFA would impinge on 
either of these possibilities, precise mechanism(s) linking GA activity to TNFR surface 
expression cannot be concluded at this point.  
 In addition to regulation of TNFR surface expression, this report further highlights 
a novel mechanism for the GA in regulating TNFα-induced gene expression that is 
independent of TNFR surface density or upstream signaling events. Discover of this 
mechanism was afforded through examination of early response genes whose 
expression was independent of protein synthesis and, presumably, protein secretion 
ruling out any role for an intermediate modulator that must the synthesized and secreted 
from the cell. As BFA co-stimulation ablated TNFα-induced gene expression through 
mechanisms that did not include changes in surface expression or signaling events from 
receptor to the nucleus, these data suggest that additional modulators of transcription 
may be involved. To the point, we hypothesize that a co-activator essential for TNFα-
induced gene expression remains sequestered to the GA under basal conditions. Upon 
TNFα stimulation, the co-activator translocates to the nucleus to regulate inflammatory 
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gene expression, thereby providing additional control over inappropriate gene 
expression except when warranted. In support of this hypothesis, emerging evidence 
demonstrates that various co-activators are localized in the GA and translocate into the 
nucleus to regulate gene transcription in response to diverse external stimuli (49-51). For 
instance, the co-activator steroid receptor coactivator (SRC)-3 is sequestered in the 
lumen of the GA before recruitment with the glucocorticoid receptor (49). Others have 
shown that multiple co-activators can be sequestered in the GA including those that 
regulate stress and hormonal transcription (50,51). While elucidation of this premise is 
underway, this hypothesis may explain the rapid effects of BFA on TNFα-induced 
inflammatory gene expression that are independent of TNFR surface expression.  
 In summary, data presented here highlight the important role for the GA in TNFα-
mediated gene expression. We show that induction of TNFα-sensitive inflammatory 
genes was ablated following Golgi collapse with BFA and that these inhibitory actions 
were specific for TNFα and not generalizable to other inflammatory stimuli. In addition, 
we report a key role for the Golgi complex in regulating TNFR cell-surface expression as 
well as TNFα-induced MAPK and NF-κB signaling. Finally, we showed that inhibition of 
the GA by BFA ablates TNFα-induced inflammatory gene expression through additional 
mechanisms that are independent of surface expression or signaling events. Based on 
these observations, we have developed a working model that highlights two mechanistic 
roles for the GA regarding TNFα-induced inflammatory gene expression (Fig.4.12). First, 
GA activity is required for maintenance of TNFR surface expression that couples TNFα 
action to signaling pathways that modulate gene expression, and second, GA activity is 
required for inflammatory gene expression through processes that are independent of 
TNFR surface expression as well as TNFα signaling events from receptor to the nucleus, 
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highlighting the possibility of a GA sequestered co-activator that translocates to the 
nucleus to impart TNFα actions on gene expression under conditions of inflammatory 
stress. 
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Figure 4.1. TNFα induces inflammatory gene expression with different kinetics. PAs 
were stimulated with 100 pM TNFα and total RNA was harvested over time post-TNFα 
prior to mRNA analysis of early genes, p28 and CCL2 (A) and late genes, EBI3 and 
CCL5 (B) using qRT-PCR.  Data were normalized to 18S rRNA and expressed relative to 
untreated control (UT).  
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Figure 4.2. TNFα-induced gene expression is independent of de novo protein 
synthesis. Cells were pretreated with 5 µM CHX for 1 hr prior to 100 pM TNFα 
stimulation. Total RNA was harvested at 2 hr post-TNFα stimulation and mRNA 
abundance of p28, CCL2, and CCL5 measured using qRT-PCR. Data were normalized to 
18S rRNA and expressed relative to untreated control (UT). Statistical significance was 
determined by ANOVA with Tukey's post-hoc analysis conducted to assess differences 
between treatment groups when p<0.05.  
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Figure. 4.3. BFA inhibits mRNA accumulation of TNFα-induced early and late gene 
expression. Cells were pretreated with 1 µM BFA for 1 hr prior to 100 pM TNFα 
stimulation. Total RNA was harvested at 2 hr (A) or 12 hr (B) post-TNFα stimulation and 
mRNA abundance of early genes, p28 and CCL2 (A) and late genes, EBI3 and CCL5 (B) 
measured using qRT-PCR. Data were normalized to 18S rRNA and expressed relative to 
untreated control (UT). Statistical significance was determined by ANOVA with Tukey's 
post-hoc analysis conducted to assess differences between treatment groups when 
p<0.05.  
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Figure 4.4. BFA inhibits TNFα-induced gene expression in PAs and ADs. PAs (A) 
and ADs (B) were pretreated for 1 hr in the presence of 1 µM BFA prior to 100 pM 
TNFα stimulation. Total RNA was harvested at 2 hr post-TNFα stimulation and mRNA 
abundance measured using qRT-PCR. Data were normalized to 18S rRNA and 
expressed relative to untreated control (UT). Statistical significance was determined by 
ANOVA with Tukey's post-hoc analysis conducted to assess differences between 
treatment groups when p<0.05.  
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Figure 4.5. BFA does not inhibit LPS- or IFNγ-induced gene expression. PAs were 
pretreated with BFA for 1 hr prior to 100 ng/ml LPS (A), or 20 ng/ml IFNγ (B) stimulation. 
Total RNA was collected at 2 hr post-stimulation and mRNA abundance assessed for 
expression of CCL2, IL-6, and/or COX-2 with qRT-PCR. Data were normalized to 18S 
rRNA and expressed relative to untreated control (UT). Statistical significance was 
determined by ANOVA with Tukey's post-hoc analysis conducted to assess differences 
between treatment groups when p<0.05.  
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Figure 4.6. Nanomolar BFA concentrations reversibly inhibit TNFα-induced 
inflammatory gene expression. (A) Cells were pretreated with BFA with varying 
concentrations for 1 hr prior to 100 pM TNFα stimulation. Total RNA was harvested at 2 hr 
post-TNFα stimulation and mRNA expression of p28 measured using qRT-PCR. (B) Cells 
were pretreated with BFA for 2 hr then BFA was removed by changing with fresh culture 
media for another 2 hr prior to TNFα stimulation. Total RNA was collected at 2 hr post-
TNFα treatment and mRNA abundance assessed for expression of CCL2 and TNFα with 
qRT-PCR. Data were normalized to 18S rRNA and expressed relative to untreated control 
(UT). Statistical significance was determined by ANOVA with Tukey's post-hoc analysis 
conducted to assess differences between treatment groups when p<0.05.  
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Figure 4.7. BFA decreases expression of TNFR1/2 on cell surface. Cells were treated 
over time with or without 1 µM of BFA and cell surface TNFR1 and TNFR2 levels were 
measured by flow cytometry. Cells were harvested, washed, and blocked with purified anti-
mouse CD16/CD32 (Fcγ III/II Receptor). Cells were subsequently stained with purified anti-
goat TNFR1 and TNFR2 followed by PE-labeled anti-donkey IgG. Staining with the TNFR1 
(blue histogram) and TNFR2 (red histogram) antibodies is compared to staining obtained 
using a purified anti-goat IgG isotype control (open histogram) (A). The mean fluorescence 
intensity is quantified and plotted in bar graph (B). Statistical significance was determined 
by ANOVA with Dunnette's post-hoc analysis conducted to assess differences from control 
(UT) when p<0.05. 
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Figure 4.8. Prolonged BFA pretreatment suppresses TNFα-induced changes in 
signaling events. Density arrested 3T3-L1 PAs were pretreated with or without 1 µM 
BFA (A) or 30 µM MNS (B) for varying time points prior to 100 pM TNFα stimulation. Cell 
lysates were collected at 15 min post-TNFα stimulation prior to immunoblot analysis of 
phosphorylated ERK, JNK, p38, and degradation of IκBα. α-tubulin was used as a 
loading control. 
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Figure 4.9. BFA co-stimulation blocks TNFα-induced gene expression. Density 
arrested 3T3-L1 PAs were pretreated with or without 1 µM BFA for varying time points 
prior to 100 pM TNFα stimulation. Total RNA was collected at 2 hr post-TNFα 
treatment and mRNA abundance assessed for expression of TNFα (A), CCL2 and p28 
(B) with qRT-PCR. Data were normalized to 18S rRNA and expressed relative to 
untreated control (UT). Statistical significance was determined by ANOVA with Tukey's 
post-hoc analysis conducted to assess differences between treatment groups p<0.05.  
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Figure 4.10. BFA co-stimulation does not suppress signaling magnitude and 
duration. Density arrested 3T3-L1 PAs were co-stimulated with or without 1 µM BFA 
and 100 pM TNFα. Cell lysates harvested over time following BFA, TNFα, or co-
stimulation prior to immunoblot analysis of phosphorylated ERK, JNK, p38 as well as 
degradation of IκBα. Abundance of α-tubulin served as a loading control. 
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Figure 4.11. BFA co-stimulation does not block TNFα-activated 
transcription factors in the nucleus. Nuclear and cytosolic extracts were 
harvested from density arrested 3T3-L1 PAs at 30 min after TNFα stimulation 
in the absence and presence of BFA (1 µM) and immunoblotted for NF-κBp65, 
phosphorylated ATF-2, and c-JUN. α-tubulin and nucleoporin were used as 
markers of cytosolic and nuclear fractions, respectively. 
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Figure 4.12. Working model for the GA action on TNFα-induced signaling and 
gene expression.  (See text for details) 
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CHAPTER V 
 
EPILOGUE 
 
 
 This dissertation established novel mechanisms regulating inflammatory gene 
expression in adipocytes. In addition, findings from the previous chapters along with 
other observations generated questions for future investigation. These preliminary 
findings and potential areas of focus will be discussed in detail in this chapter.   
 Data presented in this dissertation represent empirical evidence demonstrating 
novel mechanisms involved in adipose tissue (AT) inflammation that potentially link 
obesity with metabolic diseases. Findings presented in Chapter II collectively 
demonstrated that interleukin (IL)-12 family cytokines were abundantly expressed in AT 
and divergently regulated under conditions of genetic and diet-induced obesity that is 
associated with AT inflammation and insulin resistance (IR). Moreover, we show that IL-
27 is secreted from adipocytes and can function as an anti- or pro-inflammatory cytokine 
based on environmental cues. As we found unique function and regulation of IL-27 from 
Chapter II, we next examine the regulation of IL-27 in response to inflammatory stress in 
adipocytes. Data presented in Chapter III highlighted a novel role for histone 
deacetylases (HDACs) involving divergent mechanisms regulating IL-27 subunits p28 
and EBI3 in response to inflammation and adipocyte differentiation. These findings 
highlight epigenetic alterations on histone as critical marks in the regulation of p28 gene 
expression, suggesting that HDACs mediate the divergent expression patterns observed 
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with IL-27. Finally, findings from Chapter IV demonstrated a novel regulatory role for the 
Golgi apparatus (GA) in regulating tumor necrosis factor alpha receptor (TNFR) cell-
surface expression and subsequently TNFα-induced signaling and gene expression in 
adipocytes. Collectively, data presented in this dissertation provide new mechanisms 
that have never been studied regarding inflammatory gene expression in adipocytes that 
potentially link obesity with metabolic inflammatory diseases.  
 Data presented in this dissertation highlight two IL-27 subunits that were 
differentially regulated during inflammatory stress and adipoctye differentiation (Ch.2 & 
3). Therefore, we further examined how adipocyte differentiation regulates IL-27 
expression. Our preliminary data showed that p28 was markedly up-regulated during the 
course of adipocyte differentiation with peak induction (day4) corresponding to 
peroxisome proliferator activated receptor γ (PPARγ) activation. PPARγ is a well-
established nuclear transcription factor that is necessary and sufficient for adipocyte 
differentiation (1,2). Preliminary findings from our lab further demonstrated that induction 
of p28 required the same activators of adipocyte differentiation as PPARγ. This was 
readily apparent from our 3T3-L1 cell line stably expressing a dominant-negative isoform 
for CCAAT enhancer binding protein β (C/EBPβ) (L1-LIP), as p28 gene expression was 
lost in response to adipocyte differentiation. C/EBPβ activity is necessary for PPARγ 
induction and activation, and therefore is a key regulator during early adipocyte 
differentiation (3). Thus, similar to p28 gene expression, PPARγ gene and protein 
expression was significantly attenuated. These data suggested a potential role for both 
PPARγ and C/EBPβ in the regulation of p28 gene expression. Consistent with this 
hypothesis, others have shown PPAR and C/EBP binding site within the p28 promoter 
(4,5).  
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In contrast to p28, we also determined that EBI3 was dramatically decreased 
during adipogenesis (Ch.2 & 3). Findings from our lab determine that the decrease in 
EBI3 gene expression occurred during early adipocyte differentiation (<12 hrs). As 
initiation of 3T3-L1 adipocyte differentiation requires a hormonal cocktail that consists of 
methyl-isobutylxathine (MIX), insulin, and dexamethasone, we can subsequently tease 
out signaling pathways regulating early gene expression by isolating individual 
components of this cocktail. Our findings demonstrate that MIX was primarily 
responsible for the suppression of EBI3. Extensive studies have shown that MIX 
regulates the cAMP/PKA signaling pathway and its downstream transcription factors, 
cAMP-response element binding protein (CREB) and C/EBPβ (6,7). Subsequently, we 
observe that treatment with the cAMP/PKA inhibitor, H-89 rescued EBI3 gene repression 
during early adipogenesis, suggesting a regulatory role for cAMP/PKA in EBI3 mRNA 
expression. As the progression of obesity involves expansion of AT mass through an 
increase in size and number of adipocytes as well as recruitment of macrophages that 
contribute to inflammation, future examination of a role for adipocyte differentiation in 
regulating inflammatory gene expression in adipocytes may highlight obesity-mediated 
inflammation in AT.   
 Observations presented above highlight future studies involving inflammatory 
gene regulation during adipogenesis. In this dissertation, we also demonstrate a 
regulatory role for HDACs that is gene-type and cell-type specific, potentially contributing 
to divergent regulation of IL-27 in response to stress (Ch.3). Preliminary findings from 
our lab demonstrate that HDACs play a critical role in adipocyte inflammation as HDAC 
inhibitors attenuated expression of several TNFα-induced inflammatory genes that are 
largely shown to be involved in obesity-associated inflammation. Therefore, we raise 
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many questions from the previous chapter with regard to involvement of HDACs in 
adipocyte inflammation. For example, 1) do specific HDACs are required for TNFα-
induced inflammatory gene expression, 2) are there any cell-type specific HDACs 
regulating adipocyte inflammation based on degree of adipocyte differentiation, and 3) 
what mechanisms are involved in these processes? Anti-inflammatory actions have 
been ascribed to HDAC inhibitors in vitro and in vivo, with most studies focused on class 
I and class II HDACs as potential therapeutic targets (8,9). While many of these anti-
inflammatory properties appear to be driven by epigenetic regulation of gene 
transcription (10), HDACs can deacetylate many lysine residues on non-histone proteins 
(11). It has been shown that HDACs are highly involved in adipocyte function (12-15), 
while others demonstrate that HDACs play a crucial role in TNFα-mediated 
transcriptional activity via NF-κB dependent inflammatory gene expression (16,17). Our 
lab previously observed an anti-inflammatory role for HDAC inhibitors on TNFα-induced 
inflammatory gene expression in adipocytes. Therefore, further investigation into the role 
of HDACs in the context of adipocyte inflammation will increase our understanding of the 
epigenetic control link obesity with metabolic inflammatory diseases.   
 Finally, emerging evidence has demonstrated that the GA is a critical organelle 
involved in modifying and packaging proteins in route to their final destination (18). 
Moreover, diverse signaling factors are sequestered to the Golgi and control signaling 
cascades in response to external cues (19). Lastly, evidence demonstrates that the 
Golgi complex regulates cell-surface receptor expression and thus serves as an 
important organelle for intracellular signaling. For example, several components of the 
Ras and protein kinase A pathways reside at the Golgi, suggesting an important role for 
the GA in compartmentalizing signal transduction pathways (18,20). However, little is 
158 
 
known about the regulatory role for the GA in inflammatory signaling and gene 
expression in adipocytes. Data highlighted in Chapter IV demonstrate a novel regulatory 
role for the GA in TNFα-mediated inflammatory signaling and gene expression in 
adipocytes, as inhibition of GA function resulted in suppression of TNFα-induced gene 
expression as well as TNFR cell-surface expression and upstream signaling. However, 
suppression of inflammatory genes preceded TNFR cell-surface suppression as well as 
TNFα-induced signaling in response to the Golgi inhibition. These findings suggest an 
unreported role for the GA in inflammatory gene expression that is independent of TNFR 
surface density or signaling pathways that mediate TNFα action. Thus, it could explain 
that the GA contains co-factors that are subsequently released in response to TNFα to 
regulate early gene transcription. To further understand this, it is crucial to identify TNFα-
specific co-regulators that are localized to the Golgi and utilize gain- and loss-of-function 
studies to elucidate a functional role for these co-factors on TNFα-mediated 
inflammation. These studies would increase our understanding of a role for the GA on 
TNFα-mediated signaling pathways and gene expression in adipocytes.  
 Data presented in Chapters II-IV significantly contribute to the limited body of 
knowledge regarding inflammation in adipocytes. Use of the murine 3T3-L1 cell line 
provides an excellent model to study adipocyte inflammation, as this cell line does not 
contain other cell types (e.g., macrophages). This condition allows us to delineate 
inflammatory signaling events in a homogenous population of PAs or ADs. Furthermore, 
our findings lead to ample questions for future studies related to novel mechanisms 
involved in adipocyte inflammation through regulation of multiple pro-inflammatory genes 
that contribute to inflammation and IR. It is expected that continued examination of novel 
adipokines as well as a role for HDACs and the GA in inflammatory signaling and gene 
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expression will provide researchers with a better understanding of adipocyte biology 
involved in obesity, inflammation, and IR.  
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